KR20110025370A - New anthocyanin isolated from purple-fleshed potatoes and preparing method for the same - Google Patents
New anthocyanin isolated from purple-fleshed potatoes and preparing method for the same Download PDFInfo
- Publication number
- KR20110025370A KR20110025370A KR1020090083403A KR20090083403A KR20110025370A KR 20110025370 A KR20110025370 A KR 20110025370A KR 1020090083403 A KR1020090083403 A KR 1020090083403A KR 20090083403 A KR20090083403 A KR 20090083403A KR 20110025370 A KR20110025370 A KR 20110025370A
- Authority
- KR
- South Korea
- Prior art keywords
- acid
- compound
- alcohol
- formula
- extract
- Prior art date
Links
- 244000061456 Solanum tuberosum Species 0.000 title claims abstract description 68
- 235000002595 Solanum tuberosum Nutrition 0.000 title claims abstract description 67
- 238000000034 method Methods 0.000 title claims abstract description 20
- 235000012015 potatoes Nutrition 0.000 title claims abstract description 14
- 239000004410 anthocyanin Substances 0.000 title description 15
- 235000010208 anthocyanin Nutrition 0.000 title description 15
- 229930002877 anthocyanin Natural products 0.000 title description 15
- 150000004636 anthocyanins Chemical class 0.000 title description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 103
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 52
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 40
- 239000002253 acid Substances 0.000 claims abstract description 36
- 239000000284 extract Substances 0.000 claims abstract description 36
- 150000003839 salts Chemical class 0.000 claims abstract description 29
- 239000002904 solvent Substances 0.000 claims abstract description 17
- 239000012141 concentrate Substances 0.000 claims abstract description 13
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 11
- 238000004587 chromatography analysis Methods 0.000 claims abstract description 11
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- 238000004108 freeze drying Methods 0.000 claims abstract 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 25
- 230000003078 antioxidant effect Effects 0.000 claims description 25
- 206010028980 Neoplasm Diseases 0.000 claims description 24
- 201000011510 cancer Diseases 0.000 claims description 23
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 15
- 239000003963 antioxidant agent Substances 0.000 claims description 15
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 14
- 239000002537 cosmetic Substances 0.000 claims description 13
- 235000013305 food Nutrition 0.000 claims description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 230000002829 reductive effect Effects 0.000 claims description 10
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 9
- 235000013373 food additive Nutrition 0.000 claims description 9
- 239000002778 food additive Substances 0.000 claims description 9
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 7
- 235000019253 formic acid Nutrition 0.000 claims description 7
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 6
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 235000011054 acetic acid Nutrition 0.000 claims description 5
- 235000013376 functional food Nutrition 0.000 claims description 5
- 150000007522 mineralic acids Chemical class 0.000 claims description 5
- 150000007524 organic acids Chemical class 0.000 claims description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- 235000015165 citric acid Nutrition 0.000 claims description 4
- 239000005711 Benzoic acid Substances 0.000 claims description 3
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 235000003704 aspartic acid Nutrition 0.000 claims description 3
- 235000010233 benzoic acid Nutrition 0.000 claims description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 3
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 claims description 3
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 3
- 239000000174 gluconic acid Substances 0.000 claims description 3
- 235000012208 gluconic acid Nutrition 0.000 claims description 3
- 235000013922 glutamic acid Nutrition 0.000 claims description 3
- 239000004220 glutamic acid Substances 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 3
- 239000011976 maleic acid Substances 0.000 claims description 3
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 3
- 235000006408 oxalic acid Nutrition 0.000 claims description 3
- 230000003449 preventive effect Effects 0.000 claims description 3
- 235000019260 propionic acid Nutrition 0.000 claims description 3
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 3
- 239000011975 tartaric acid Substances 0.000 claims description 3
- 235000002906 tartaric acid Nutrition 0.000 claims description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 235000011087 fumaric acid Nutrition 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims 1
- 235000011007 phosphoric acid Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 21
- 239000000203 mixture Substances 0.000 abstract description 19
- 239000000126 substance Substances 0.000 abstract description 15
- 230000001093 anti-cancer Effects 0.000 abstract description 11
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 44
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 37
- 235000019441 ethanol Nutrition 0.000 description 28
- 235000002639 sodium chloride Nutrition 0.000 description 22
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 20
- -1 anthocyanin compound Chemical class 0.000 description 19
- 235000010323 ascorbic acid Nutrition 0.000 description 16
- 239000011668 ascorbic acid Substances 0.000 description 16
- 229960005070 ascorbic acid Drugs 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 230000002401 inhibitory effect Effects 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- 229910052799 carbon Inorganic materials 0.000 description 14
- 235000006708 antioxidants Nutrition 0.000 description 13
- 230000002292 Radical scavenging effect Effects 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 11
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 10
- 235000000346 sugar Nutrition 0.000 description 10
- 229930003799 tocopherol Natural products 0.000 description 10
- 235000010384 tocopherol Nutrition 0.000 description 10
- 239000011732 tocopherol Substances 0.000 description 10
- 229960001295 tocopherol Drugs 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000012153 distilled water Substances 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000006071 cream Substances 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 7
- 235000008504 concentrate Nutrition 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 6
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 6
- 230000003859 lipid peroxidation Effects 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 6
- 238000002953 preparative HPLC Methods 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 150000007965 phenolic acids Chemical class 0.000 description 5
- 239000000049 pigment Substances 0.000 description 5
- 229920001592 potato starch Polymers 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000002335 preservative effect Effects 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 239000006188 syrup Substances 0.000 description 5
- 235000020357 syrup Nutrition 0.000 description 5
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 4
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 4
- 238000001052 heteronuclear multiple bond coherence spectrum Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 235000020778 linoleic acid Nutrition 0.000 description 4
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 3
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 3
- 102100020870 La-related protein 6 Human genes 0.000 description 3
- 108050008265 La-related protein 6 Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920001214 Polysorbate 60 Polymers 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- KYIKRXIYLAGAKQ-UHFFFAOYSA-N abcn Chemical compound C1CCCCC1(C#N)N=NC1(C#N)CCCCC1 KYIKRXIYLAGAKQ-UHFFFAOYSA-N 0.000 description 3
- 150000001336 alkenes Chemical class 0.000 description 3
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 3
- 229960003459 allopurinol Drugs 0.000 description 3
- 229940087168 alpha tocopherol Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 238000011284 combination treatment Methods 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000000990 heteronuclear single quantum coherence spectrum Methods 0.000 description 3
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 3
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 3
- 229940113124 polysorbate 60 Drugs 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 3
- 235000019204 saccharin Nutrition 0.000 description 3
- 229940081974 saccharin Drugs 0.000 description 3
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 3
- 230000002000 scavenging effect Effects 0.000 description 3
- 235000013599 spices Nutrition 0.000 description 3
- 229960000984 tocofersolan Drugs 0.000 description 3
- 239000002076 α-tocopherol Substances 0.000 description 3
- 235000004835 α-tocopherol Nutrition 0.000 description 3
- 229930013915 (+)-catechin Natural products 0.000 description 2
- 235000007219 (+)-catechin Nutrition 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 108010093894 Xanthine oxidase Proteins 0.000 description 2
- 102100033220 Xanthine oxidase Human genes 0.000 description 2
- 229940009456 adriamycin Drugs 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 238000002792 antioxidant assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229950001002 cianidanol Drugs 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- VEVZSMAEJFVWIL-UHFFFAOYSA-O cyanidin cation Chemical group [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC=C(O)C(O)=C1 VEVZSMAEJFVWIL-UHFFFAOYSA-O 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000007760 free radical scavenging Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 239000000401 methanolic extract Substances 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 235000009048 phenolic acids Nutrition 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- STGNLGBPLOVYMA-MAZDBSFSSA-N (E)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O STGNLGBPLOVYMA-MAZDBSFSSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- XILIYVSXLSWUAI-UHFFFAOYSA-N 2-(diethylamino)ethyl n'-phenylcarbamimidothioate;dihydrobromide Chemical compound Br.Br.CCN(CC)CCSC(N)=NC1=CC=CC=C1 XILIYVSXLSWUAI-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 241000554155 Andes Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 241000976924 Inca Species 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- BXEZTCOKOLHMKY-IPEHMYPNSA-O Petanin Natural products O=C(O[C@@H]1[C@H](O)[C@H](O)[C@H](OC[C@@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](Oc3c(-c4cc(OC)c(O)c(O)c4)[o+]c4c(c(O[C@H]5[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O5)cc(O)c4)c3)O2)O[C@H]1C)/C=C/c1ccc(O)cc1 BXEZTCOKOLHMKY-IPEHMYPNSA-O 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- LXEKPEMOWBOYRF-UHFFFAOYSA-N [2-[(1-azaniumyl-1-imino-2-methylpropan-2-yl)diazenyl]-2-methylpropanimidoyl]azanium;dichloride Chemical compound Cl.Cl.NC(=N)C(C)(C)N=NC(C)(C)C(N)=N LXEKPEMOWBOYRF-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- SOIFLUNRINLCBN-UHFFFAOYSA-N ammonium thiocyanate Chemical compound [NH4+].[S-]C#N SOIFLUNRINLCBN-UHFFFAOYSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002019 anti-mutation Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940079894 benzophenone-9 Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000005100 correlation spectroscopy Methods 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000007336 cyanidin Nutrition 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000010389 delta-tocopherol Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- QDCHWIWENYCPIL-UHFFFAOYSA-L disodium;4-hydroxy-5-(2-hydroxy-4-methoxy-5-sulfonatobenzoyl)-2-methoxybenzenesulfonate Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC(S([O-])(=O)=O)=C(OC)C=C1O QDCHWIWENYCPIL-UHFFFAOYSA-L 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 229960002089 ferrous chloride Drugs 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 238000005858 glycosidation reaction Methods 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 1
- 238000005570 heteronuclear single quantum coherence Methods 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 230000002700 inhibitory effect on cancer Effects 0.000 description 1
- 229940030980 inova Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 229930015717 petunidin Natural products 0.000 description 1
- 235000006384 petunidin Nutrition 0.000 description 1
- QULMBDNPZCFSPR-UHFFFAOYSA-N petunidin chloride Chemical compound [Cl-].OC1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O)=C1 QULMBDNPZCFSPR-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 235000007794 yellow potato Nutrition 0.000 description 1
- 239000002446 δ-tocopherol Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
- C07H1/08—Separation; Purification from natural products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Botany (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
본 발명은 유색감자로부터 분리한 신규 안토시아닌 화합물과 그의 제조방법에 관한 것이다.The present invention relates to a novel anthocyanin compound isolated from colored potatoes and a method for producing the same.
감자(Solanum tuberosum L.)는 가지과(Solanaceae)에 속하는 다년생 식물로서 원산지는 남아메리카 안데스산맥의 중부고산지, 즉 칠레의 중북부로부터 볼리비아, 페루, 에쿠아도르에 이르는 지역으로 평가하고 있고, 고대 잉카국에서는 감자를 식용으로 재배하였다는 보고가 있고, 현재와 같은 재배종은 1,000여년전부터 재배되었으며, 16세기에 스페인 사람들에 의해 서구로 전래되었다. 우리나라에는 1830년 경 네덜란드인에 의해 중국으로부터 씨감자가 도입되어 재배되기 시작하였다. Potato ( Solanum tuberosum L.) is a perennial plant belonging to the family Solanaceae, originating from the central highlands of the Andes of South America, ranging from the mid-North of Chile to Bolivia, Peru, and Ecuador, and in ancient Inca countries It is reported that it was edible for food, and the same cultivar was cultivated more than 1,000 years ago, and was introduced to the West by the Spanish in the 16th century. In Korea, seed potatoes were introduced and cultivated from China by the Dutch around 1830.
감자는 생육기간이 짧고, 단위면적당 생산량이 높으며 환경적응성도 비교적 강하여 세계 130 여개 나라에서 재배되며, 벼, 밀, 콩, 옥수수 등과 함께 세계주요 식량작물로 여겨지고 있다. 현재 전 세계적으로 재배되고 있는 감자의 괴경색은 백색이나 연황색이 주종을 이루지만 자연계에는 괴경 색상 형성에 관여하는 유전자의 다양성에 의해 적색 및 보라색 등, 안토시아닌(anthocyanin) 색소를 함유하고 있는 다양한 색상의 유색감자도 존재한다. Potatoes are grown in more than 130 countries because of their short growing period, high yield per unit area, and high environmental adaptability, and are considered to be the world's major food crops alongside rice, wheat, soybeans, and corn. Potato tubers currently grown around the world are predominantly white or light yellow, but in nature, various colors containing anthocyanin pigments, such as red and purple, due to the diversity of genes involved in tuber color formation. There is also a colored potato.
현재 감자는 우리나라에서도 식용으로써의 이용이 대부분이며, 우리나라 전역에서 재배되고 있으며, 식용으로 사용하는 감자는 대부분 괴경색이 백색-연황색을 나타내는 일반종이 사용되고 있고, 최근 소비자의 기호와 건강 기능성에 관심이 고조되면서 국내에서도 일부 유색감자의 재배가 시작되고 있는 실정이다. Currently, potato is mostly used as food in Korea, and it is grown all over Korea, and most of potato used for food is common species with tuber color in white-yellowish color. As this heightens, some colored potatoes are being cultivated in Korea.
덩이줄기 내부에 적색 또는 보라색 안토시아닌(anthocyanin) 색소를 함유하는 유색감자는 그들만이 가지는 색깔과 독특한 맛을 함유하고 있을 뿐만 아니라 샐러드나 튀김용으로 사용할 경우 요리 후에도 그 색상을 유지하고 있어 유색감자에 대한 소비자의 요구도가 증대되고 있으며, 유색감자는 다량의 안토시아닌(anthocyanin) 색소와 페놀산(phenolic acid)을 함유하고 있는 것으로 보고되고 있고, 미국의 경우 채소로서 소비되는 유색감자의 양은 1인당 135 파운드에 이르고 있다.Colored potatoes containing red or purple anthocyanin pigments in tubers not only have their own color and unique taste, but also retain their color after cooking when used for salads or fries. Increasing consumer demand for color, color potato is reported to contain a large amount of anthocyanin pigments and phenolic acid, in the United States the amount of color potato consumed as vegetables is 135 pounds per person Is reaching.
최근 유색감자 추출물의 항산화, 항돌연변이, 특정 암세포의 생장저해 효과 가 보고 된 바 있으나, 각 활성의 근원물질에 대한 정보는 전무한 상황에 있다. Recently, anti-oxidation, anti-mutation and growth inhibition effects of certain cancer cells of colored potato extract have been reported, but there is no information on the source of each activity.
본 발명은 유색감자가 가지는 상기 활성의 근원물질을 확인하고 이를 분리 동정하여 제공하는데 그 목적이 있다.An object of the present invention is to identify the source material of the activity having a colored potato and to identify and provide it.
상기한 목적을 달성하기 위한 일례로서 본 발명은, 다음 화학식 1로 표시되는 신규화합물 및 그의 염을 제공한다.As an example for achieving the above object, the present invention provides a novel compound represented by the following formula (1) and salts thereof.
[화학식 1][Formula 1]
상기한 목적을 달성하기 위한 다른 일례로서 본 발명은, 상기 화학식 1로 표시되는 화합물 또는 그의 염을 포함하는 것을 특징으로 하는 유색감자 추출물을 제 공한다.As another example for achieving the above object, the present invention provides a colored potato extract, characterized in that it comprises a compound represented by the formula (1) or a salt thereof.
상기한 목적을 달성하기 위한 다른 일례로서 본 발명은, 유색감자를 산(acid)이 함유된 알콜로 추출하고 감압농축하여 알콜 추출물을 얻는 단계, 상기 알콜 추출물을 농축하고 산함유 물과 알콜의 혼합용매에 용해시킨 후 크로마토그래피(chromatography)를 수행하고 각 용매별 분획을 농축하여 농축액을 얻는 단계, 상기 농축액 중 활성분획을 농축한 활성분획 농축액을 산함유 알콜에 용해시킨 후 크로마토그래피를 수행하여 활성분획을 모으는 단계, 및 상기 활성분획을 크로마토그래피로 분리하고 용매를 제거한 후 냉동건조하여 목적화합물을 얻는 단계를 포함하여 이루어지는 것을 특징으로 하는 화학식 1의 화합물의 제조방법을 제공한다.As another example for achieving the above object, the present invention is to extract the colored potato with an alcohol containing acid and concentrated under reduced pressure to obtain an alcohol extract, concentrating the alcohol extract and mixing the acid-containing water and alcohol After dissolving in a solvent to perform chromatography (chromatography) and to concentrate the fractions for each solvent to obtain a concentrate, the active fraction concentrate the active fraction of the concentrate in the acid-containing alcohol and then chromatograph the activity Collecting the fractions, and separating the active fractions by chromatography, removing the solvent, and lyophilizing to obtain a target compound.
상기 제조방법에서, 산(acid)함유 알콜과 산함유 물에서 산은 0.1 내지 5 %(w/w) 포함되는 것이 더욱 바람직하다.In the above production method, the acid in the acid-containing alcohol and the acid-containing water is more preferably contained 0.1 to 5% (w / w).
상기한 목적을 달성하기 위한 다른 일례로서 본 발명은, 상기 화학식 1로 나타내는 화합물 또는 약학적으로 허용되는 그의 염, 또는 이를 포함하는 유색감자 추출물을 함유하는 것을 특징으로 하는 항암제를 제공한다.As another example for achieving the above object, the present invention provides an anticancer agent comprising a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof, or a colored potato extract comprising the same.
상기한 목적을 달성하기 위한 다른 일례로서 본 발명은, 상기 화학식 1로 나타내는 화합물 또는 약학적으로 허용되는 그의 염, 또는 이를 포함하는 유색감자 추출물을 유효성분으로 함유하는 것을 특징으로 하는 항산화제를 제공한다.As another example for achieving the above object, the present invention provides an antioxidant comprising a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof, or a colored potato extract comprising the same as an active ingredient do.
상기한 목적을 달성하기 위한 다른 일례로서 본 발명은, 상기 항산화제를 함유하는 것을 특징으로 하는 화장료를 제공한다.As another example for achieving the above object, the present invention provides a cosmetic comprising the antioxidant.
상기한 목적을 달성하기 위한 다른 일례로서 본 발명은, 상기 화학식 1로 나 타내는 화합물 또는 식품학적으로 허용되는 그의 염, 또는 이를 포함하는 유색감자 추출물을 유효성분으로 함유하는 것을 특징으로 하는 암의 예방 기능을 갖는 식품첨가제를 제공한다.As another example for achieving the above object, the present invention, the compound represented by the formula (1) or food-acceptable salts thereof, or a colored potato extract comprising the same as an active ingredient, prevention of cancer It provides a food additive having a function.
상기한 목적을 달성하기 위한 다른 일례로서 본 발명은, 상기 식품첨가제를 함유하는 것을 특징으로 하는 암의 예방 기능을 갖는 건강기능식품을 제공한다.As another example for achieving the above object, the present invention provides a health functional food having a preventive function of cancer, characterized by containing the food additive.
이하 본 발명을 구체적으로 설명한다.Hereinafter, the present invention will be described in detail.
본 발명의 발명자들은 일반 황색감자와는 달리 유색감자 괴경의 메탄올 추출물로부터 1종의 안토시아닌(anthocyanin) 화합물을 순수분리 하였으며, NMR 등 기기분석을 이용하여 구조 동정한 결과 현재까지 알려지지 않은 신규 화합물임을 확인하고 이를 페츄나닌(petunanin) JY 라고 명명하였다.The inventors of the present invention, unlike the general yellow potato, purely separated one anthocyanin compound from the methanol extract of the colored potato tuber, and confirmed the structure by using NMR and instrumental analysis to confirm that it is a new compound which is unknown until now. It was named petunanin JY.
상기 신규화합물은 적색의 분말상으로, 분자량은 1110이고, 분자식은 C53H57O26 +이다. The novel compound is a red powder, molecular weight is 1110, the molecular formula is C 53 H 57 O 26 + .
상기 화학식 1로 표시되는 본 발명의 신규화합물은 약학적으로 허용 가능한 염, 식품학적으로 형태로 사용할 수 있으며, 염으로는 약학적 또는 식품학적으로 허용 가능한 유리산(free acid)에 의해 형성된 산 부가염이 유용하다. The novel compounds of the present invention represented by Chemical Formula 1 may be used in the form of pharmaceutically acceptable salts or foods, and as salts, the addition of an acid formed by the free acid of the pharmaceutically or foods acceptable salts. Salts are useful.
상기 화학식 1로 표시되는 본 발명의 신규화합물은 당해 기술 분야에서 통상적인 방법에 따라 약학적 또는 식품학적으로 허용되는 산 부가염을 형성할 수 있다. 산으로는 유기산과 무기산을 사용할 수 있으며, 무기산으로는 염산, 브롬산, 황산, 인산 등을 사용할 수 있고 유기산으로는 구연산(citric acid), 초산, 젖산, 주석산(tartaric acid), 말레인산, 푸마르산(fumaric acid), 포믹산, 프로피온산(propionic acid), 옥살산, 트리플루오로아세트산, 벤조산, 글루콘산, 메탄술폰산, 글리콜산, 숙신산, 4-톨루엔술폰산, 갈룩투론산, 엠본산, 글루탐산 또는 아스파르트산 등을 사용할 수 있다.The novel compounds of the present invention represented by Chemical Formula 1 may form pharmaceutically or food acceptable acid addition salts according to a conventional method in the art. Organic acids and inorganic acids may be used as acids, hydrochloric acid, bromic acid, sulfuric acid, phosphoric acid, etc. may be used as inorganic acids, citric acid, acetic acid, lactic acid, tartaric acid, maleic acid, fumaric acid ( fumaric acid), formic acid, propionic acid, oxalic acid, trifluoroacetic acid, benzoic acid, gluconic acid, methanesulfonic acid, glycolic acid, succinic acid, 4-toluenesulfonic acid, galluxuronic acid, embonic acid, glutamic acid or aspartic acid Can be used.
본 발명은 상기 화학식 1로 표시되는 신규화합물 및 그의 염을 포함하는 유색감자 추출물을 포함하며, 이러한 유색감자 추출물을 식품 또는 화장료의 성분으로 사용할 수 있을 것이다.The present invention includes a colored potato extract comprising a novel compound represented by the formula (1) and salts thereof, and such colored potato extract may be used as a component of food or cosmetics.
상기 유색감자 추출물은 초음파 추출법, 여과법, 환류추출법 등 당업계의 통상적인 추출방법을 사용할 수 있으며 추출 시 초산, 포믹산, 구연산 등을 사용할 수 있다. 상기 추출물 제조 방법을 달리 하여도 신규 화합물의 정량적 데이터는 차이가 날 수 있으나 정성적 데이터는 차이가 나지 않는다. The colored potato extract may be used in the conventional extraction methods, such as ultrasonic extraction, filtration, reflux extraction method and may be used for acetic acid, formic acid, citric acid and the like. Even if the extract preparation method is different, the quantitative data of the new compound may vary, but the qualitative data does not differ.
또한 본 발명은 상기 화학식 1로 표시되는 본 발명의 신규화합물을 추출, 분리 및 정제하는 방법을 제공한다.In another aspect, the present invention provides a method for extracting, separating and purifying the novel compound of the present invention represented by the formula (1).
본 발명의 제조방법은, 먼저, 유색감자를 산함유 알콜로 추출하고 감압농축하여 알콜 추출물을 얻는 단계를 포함한다. 상기 알콜은 탄소수 1 내지 3의 알콜을 사용할 수 있을 것이며, 산은 유기산과 무기산을 사용할 수 있으며, 무기산으로는 염산, 브롬산, 황산, 인산 등을 사용할 수 있고 유기산으로는 구연산(citric acid), 초산, 젖산, 주석산(tartaric acid), 말레인산, 푸마르산(fumaric acid), 포믹산, 프로피온산(propionic acid), 옥살산, 트리플루오로아세트산, 벤조산, 글루콘산, 메탄술폰산, 글리콜산, 숙신산, 4-톨루엔술폰산, 갈룩투론산, 엠본산, 글루탐산 또는 아스파르트산 등을 선택 사용할 수 있을 것이다.The manufacturing method of the present invention includes, first, extracting a colored potato with an acid-containing alcohol and concentrating under reduced pressure to obtain an alcohol extract. The alcohol may be an alcohol having 1 to 3 carbon atoms, an acid may be an organic acid and an inorganic acid, hydrochloric acid, bromic acid, sulfuric acid, phosphoric acid, etc. may be used as an inorganic acid, citric acid, acetic acid as an organic acid , Lactic acid, tartaric acid, maleic acid, fumaric acid, formic acid, propionic acid, oxalic acid, trifluoroacetic acid, benzoic acid, gluconic acid, methanesulfonic acid, glycolic acid, succinic acid, 4-toluenesulfonic acid It may be used to select galgluturonic acid, embon acid, glutamic acid or aspartic acid.
유색감자는 적색, 자색을 띠는 알려진 유색감자로서, 본 발명에서는 농촌진흥청에 품종 등록된 자영(Solanum tuberosum L. cv Jayoung)을 사용하였으나, 이에 한정되는 것은 아니며, 시판하는 유색감자 또는 재배된 유색감자를 다양하게 사용할 수 있을 것이다.Colored potato is known as a red, purple colored potato, in the present invention, but the use of Solanum tuberosum L. cv Jayoung varieties registered with the Rural Development Administration, but is not limited thereto, commercially available colored potato or cultivated colored potato There will be a variety of potatoes available.
상기 유색감자의 껍질을 제거하고 세절한 생체를 산이 소량 함유된 알콜을 사용하여 상온에서 24 내지 48 시간 추출한다. 유색감자 생체량은 산함유 알콜 중 5 내지 10 %(w/w) 정도로 포함시키는 것이 바람직할 것이다. 상기 알콜에 산을 포함시키는 것은 유색감자에 함유된 색소의 안정성을 증가시키기 위한 것이며, 산의 함량은 사용된 산함유 알콜 중 0.1 내지 5 %(w/w) 정도가 되도록 하며, 염산을 사용할 경우에는 0.1 내지 1 %(w/w), 유기산을 사용할 경우에는 0.1 내지 5 %(w/w) 범위로 사용할 수 있을 것이다. The skin of the colored potato is removed and the fine living body is extracted at room temperature for 24 to 48 hours using an alcohol containing a small amount of acid. It may be desirable to include colored potato biomass in the range of 5-10% (w / w) in the acid-containing alcohol. Inclusion of the acid in the alcohol is to increase the stability of the pigment contained in the colored potato, the acid content is to be about 0.1 to 5% (w / w) of the acid-containing alcohol used, when using hydrochloric acid In the case of using an organic acid of 0.1 to 1% (w / w), it may be used in the range of 0.1 to 5% (w / w).
상기 알콜 추출물을 농축하고 산함유 물과 알콜 혼합용매에 용해시킨 후 크로마토그래피(chromatography)를 수행하여 각 용매별 분획을 얻는 단계를 거친다.The alcohol extract is concentrated, dissolved in an acid-containing water and alcohol mixed solvent, and chromatographed to obtain a fraction for each solvent.
이를 상세하게 설명하면, 얻어진 알콜 추출물을 농축한 다음 산함유 물(증류수)에 용해시키고 옥타데실실릴화한 실리카 등과 같은 실리카겔이 충진된 칼럼에 산함유 물과 산함유 알콜의 비율을 변화시키면서 크로마토그래피를 실시하여 각 용매별 분획을 얻는다. In detail, the obtained alcohol extract was concentrated and then chromatographed while changing the ratio of acid-containing water and alcohol-containing alcohol in a column filled with silica gel such as silica, which was dissolved in acid-containing water (distilled water) and octadecylsilylated silica. To obtain a fraction for each solvent.
상기 얻어진 각 용매별 분획 중 활성분획을 농축한 활성분획 농축액을 산함유 알콜에 용해시킨 후 크로마토그래피를 수행하여 활성분획을 모으는 단계를 거친다.After dissolving the active fraction concentrate of the active fraction in each of the solvent fractions obtained in an acid-containing alcohol and performing a chromatography to collect the active fractions.
이를 상세하게 설명하면, 물과 알콜의 비율을 달리하여 크로마토그래피를 수행한 후 얻어진 각 분획 중에서 주요 안토시아닌이 함유되어있는 분획을 농축건조하는데, 40 ℃ 조건의 감압농축 건조기를 사용하는 것이 바람직하며, 이와 같이 농축건조하여 활성분획 농축액을 얻는다. To explain this in detail, after performing chromatography by varying the ratio of water and alcohol, the fractions containing the major anthocyanins in each fraction obtained are concentrated to dry, and it is preferable to use a reduced pressure concentrated dryer at 40 ° C. Thus concentrated to dryness to obtain an active fraction concentrate.
상기 활성분획을 크로마토그래피로 분리하고 용매를 제거한 후 냉동건조하여 목적화합물을 얻는 단계를 포함하여 상기 화학식 1의 화합물을 얻을 수 있다.The active fraction may be separated by chromatography, the solvent is removed, and lyophilized to obtain the target compound, thereby obtaining the compound of
즉, 활성분획을 산함유 알콜(20%)에 용해하고 Preparative-HPLC 등을 사용하여 고순도 분리를 실시하여 목적화합물을 얻었다. 상기 목적화합물을 FAB-MS, NMR 등의 방법으로 구조를 동정하여, 상기 화학식 1로 표시되는 신규 화합물을 얻었으며, 이를 페츄나닌(petunanin) JY 라고 명명하였다.That is, the active fraction was dissolved in an acid-containing alcohol (20%) and subjected to high purity separation using Preparative-HPLC to obtain the target compound. The target compound was identified by FAB-MS, NMR, or the like to obtain a new compound represented by Chemical Formula 1, which was named as petunanin JY.
얻어진 상기 신규화합물은 정상세포에 대한 부작용이 거의 없으며, 높은 항산화활성과 항암활성을 나타내므로 암의 치료와 예방 및 다양한 질병의 치료제와 병용되어 질병의 치료 및 예방 효과를 증대시키는 효과를 기대할 수 있다.The new compound obtained has little side effects on normal cells, and exhibits high antioxidant and anticancer activity, so that the new compound can be used in combination with therapeutic agents for the treatment and prevention of cancer and for the treatment of various diseases. .
또한, 본 발명은 상기 화학식 1로 표시되는 신규화합물 및 약학적으로 허용되는 그의 염을 함유하는 항암제 및 항산화제를 제공한다. In addition, the present invention provides an anticancer agent and an antioxidant containing the novel compound represented by Formula 1 and a pharmaceutically acceptable salt thereof.
상기의 항암제는 항산화활성과 항암활성을 나타내는 화학식 1로 표시되는 화 합물 또는 약학적으로 허용 가능한 그의 염을 유효성분으로 함유하므로 암세포의 생육을 저해함으로써 다양한 암을 저해하거나 예방하는데 유용하게 이용될 수 있다. 또한 항산화제는 지질과산화를 저해하고 활성산소 제거능이 우수하므로 다양한 질병의 치료제와 병용할 경우 질병의 저해와 예방에 유용하게 이용될 수 있다.Since the anticancer agent contains a compound represented by Formula 1 or an pharmaceutically acceptable salt thereof as an active ingredient showing antioxidant activity and anticancer activity, it can be usefully used to inhibit or prevent various cancers by inhibiting growth of cancer cells. have. In addition, since antioxidants inhibit lipid peroxidation and have an excellent ability to remove free radicals, they may be usefully used for the inhibition and prevention of diseases when used in combination with therapeutic agents for various diseases.
상기 신규화합물은 임상 투여시에 경구 또는 비경구로 투여, 예를 들어 정맥 내, 피하, 복강 내 또는 국소 적용할 수 있으며, 일반적인 의약품 제제의 형태로 사용될 수 있다.The novel compounds can be administered orally or parenterally, for example, intravenously, subcutaneously, intraperitoneally or topically, during clinical administration and can be used in the form of general pharmaceutical formulations.
본 발명의 신규화합물을 포함하는 약학적 조성물은 경구 투여용 제형, 예를 들면 정제, 트로치제(troches), 로렌지(lozenge), 수용성 또는 유성현탁액, 조제분말 또는 과립, 에멀젼, 하드 또는 소프트 캡슐, 시럽 또는 엘릭시르제(elixirs)로 제제화된다. 정제 및 캡슐 등의 제형으로 제제하기 위해 락토오스, 사카로오스, 솔비톨, 만니톨, 전분, 아밀로펙틴, 셀룰로오스 또는 젤라틴과 같은 결합제; 디칼슘 포스페이트와 같은 부형제; 옥수수 전분 또는 고구마 전분과 같은 붕괴제; 스테아르산 마그네슘, 스테아르산 칼슘, 스테아릴푸마르산 나트륨 또는 폴리에틸렌글리콜 왁스와 같은 윤활유가 함유된다. 캡슐제형의 경우는 상기에서 언급한 물질 이외에도 지방유와 같은 액체 담체를 함유한다.Pharmaceutical compositions comprising the novel compounds of the invention may be formulated for oral administration such as tablets, troches, lozenges, aqueous or oily suspensions, prepared powders or granules, emulsions, hard or soft capsules. , Syrup or elixirs. Binders such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose or gelatin for preparation in formulations such as tablets and capsules; Excipients such as dicalcium phosphate; Disintegrants such as corn starch or sweet potato starch; Lubricants such as magnesium stearate, calcium stearate, sodium stearyl fumarate or polyethylene glycol wax. Capsules contain liquid carriers, such as fatty oils, in addition to the substances mentioned above.
또한, 본 발명의 신규화합물을 포함하는 약학적 조성물은 비경구로 투여할 수 있으며, 비경구 투여는 피하주사, 정맥주사, 근육내 주사 또는 흉부내 주사 주입방식에 의한다. 비경구 투여용 제형으로 제제화하기 위해서는 상기 신규화합물을 안정제 또는 완충제와 함께 물에서 혼합하여 용액 또는 현탁액으로 제조하고 이를 앰플 또는 바이알의 단위 투여형으로 제제한다.In addition, pharmaceutical compositions comprising the novel compounds of the present invention may be administered parenterally, and parenteral administration may be by subcutaneous injection, intravenous injection, intramuscular injection or intrathoracic injection. To formulate into parenteral dosage forms, the novel compounds are mixed in water with stabilizers or buffers to prepare solutions or suspensions, which are formulated in unit dosage forms of ampoules or vials.
상기 화학식 1로 표시되는 본 발명의 신규화합물의 유효 용량은 일반적으로 성인 환자 체중 1 kg 당 1 내지 50 mg/일이고, 바람직하기로는 5 내지 20 mg/일이며, 의사 또는 약사의 판단에 따라 일정 시간 간격으로 1 일 수회, 바람직하기로는 하루 2 회 내지 3 회 분할 투여될 수 있다.The effective dose of the novel compound of the present invention represented by Chemical Formula 1 is generally 1 to 50 mg / day, preferably 5 to 20 mg / day, per kg of adult patient, and is fixed according to the judgment of a doctor or pharmacist. It may be administered several times a day at intervals of time, preferably two to three times a day.
상기 화학식 1로 표시되는 본 발명의 신규화합물은 특이적 암세포주에 활성을 나타내는 것으로 생각되며, 특정 암세포주에 대한 높은 항암활성을 나타낼 뿐만 아니라, 정상세포에는 크게 영향을 미치지 않기 때문에 항암제로서의 활용 및 기존항암제의 안정성 확보를 위한 병용처리 안정제 및 치료효율을 높일 수 있는 상승제로 활용되어질 수 있을 것으로 판단된다. The novel compounds of the present invention represented by the above formula (1) are considered to exhibit activity on specific cancer cell lines, and exhibit high anticancer activity against specific cancer cell lines, and thus do not significantly affect normal cells, and thus are used as anticancer agents. It is expected to be used as a combination treatment stabilizer and a synergist to increase the treatment efficiency to secure the stability of existing anticancer drugs.
또한, 본 발명의 신규화합물은 정상세포에 안전하면서 높은 항산화활성을 가지므로, 인체 내에 자유 라디칼이나 활성 유해 산소의 증가에 의하여 피부의 주름이 증가하거나 탄력 감소를 비롯하여, 기미, 주근깨 및 검버섯 등의 색소 침착 등으로 대표되는 피부의 노화를 억제할 수 있을 것으로 예상되며, 따라서, 상기 항산화제를 화장료에 포함시켜 사용할 수 있을 것이다. 이러한 신규화합물은 분리된 화합물의 상태로 화장료에 포함시켜 사용하는 것도 좋으나, 유색감자 추출물의 형태로 화장료 중에 포함시키는 것이 경제적인 측면에서 바람직할 것이다. 본 발명의 신규화합물 또는 그의 염을 유색감자 추출물의 상태로 화장료 중에 포함시킬 경우 화장료 총 중량 중 0.001 내지 20 %(w/w), 바람직하기로는 0.01 내지 10 %(w/w) 범위로 사용할 수 있을 것이며, 함량이 상기 범위 미만이면 항산화효과 활성의 발현 으로 인한 피부 노화 방지 효과가 미미할 것이고, 함량이 상기 범위를 초과하여 많으면 초과 투입에 따른 상승효과가 적어 경제적이지 못한 경향이 있다.In addition, since the novel compounds of the present invention are safe to normal cells and have high antioxidant activity, wrinkles of the skin are increased or elasticity is reduced by increasing free radicals or active harmful oxygen in the human body, such as spots, freckles, and brown mushrooms. It is expected that the aging of the skin, which is represented by pigmentation and the like, can be suppressed, and therefore, the antioxidant can be used in cosmetics. Such a novel compound may be used in the form of a separated compound in the cosmetics, but it may be preferable to include in the cosmetics in the form of colored potato extract in terms of economics. When the new compound of the present invention or a salt thereof is included in cosmetics in the form of colored potato extract, it can be used in the range of 0.001 to 20% (w / w), preferably 0.01 to 10% (w / w) of the total weight of the cosmetic. If the content is less than the above range, the anti-aging effect of the skin due to the expression of antioxidant activity will be insignificant. If the content is more than the above range, the synergistic effect due to the excess input is less likely to be economical.
본 발명의 신규화합물 또는 그의 염, 또는 이를 포함하는 유색감자 추출물의 상태로 화장료에 도입하고자 할 경우, 이들 외에 통상적으로 화장료 성분으로 사용되는 안정화제, 용해화제, 비타민, 안료 및 향료 등과 같은 성분들을 포함할 수 있다. 또한, 상기 화장료는 제형이 특별히 한정되지 않고 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어 유연화장수, 수렴화장수, 영양화장수, 에센스, 로션, 아이크림, 영양크림, 마사지크림, 클렌징크림, 클렌징 폼, 클렌징 워터, 파우더, 팩, 젤, 연고, 패취, 분무제 등의 제형으로 제조될 수 있을 것이다. When introducing a new compound of the present invention or a salt thereof, or a colored potato extract containing the same to the cosmetics, ingredients such as stabilizers, solubilizers, vitamins, pigments and fragrances commonly used as cosmetic ingredients It may include. In addition, the cosmetic formulation is not particularly limited and may be prepared in any formulation commonly prepared in the art, for example, softening water, astringent makeup, nutrient cosmetics, essences, lotions, eye cream, nutrition cream, massage It may be prepared in the form of creams, cleansing creams, cleansing foams, cleansing water, powders, packs, gels, ointments, patches, sprays and the like.
또한, 식용되는 유색감자로부터 분리 동정되었으므로 인체에 안정하여 식품에 첨가하여 사용하기에 적합하므로, 암의 예방 기능을 갖는 식품첨가제, 건강기능식품으로 개발될 수 있다. In addition, since it has been identified and separated from the edible colored potatoes, it is stable to the human body and is suitable for use in addition to food, and thus can be developed as a food additive and health functional food having a function of preventing cancer.
식품첨가제로 개발시에는 식품학적으로 허용되는 식품첨가보조제를 사용할 수 있을 것이며, 식품의 주· 부원료로 하여 제조되거나 다른 식품에 첨가될 수 있다.When developing as a food additive, food additives may be used as food additives, and may be prepared as a main or secondary ingredient of the food or added to other foods.
본 발명의 신규화합물 또는 그의 염을 유색감자 추출물의 상태로 식품첨가제, 또는 건강기능식품 중에 포함시킬 경우 총 중량 중 0.01 내지 50 %(w/w), 바람직하기로는 1 내지 30 %(w/w) 범위로 사용할 수 있을 것이며, 함량이 상기 범위 미 만이면 항산화효과 활성의 발현으로 인해 취득되는 효과가 미미할 것이고, 함량이 상기 범위를 초과하여 많으면 초과 투입에 따른 상승효과가 적어 경제적이지 못한 경향이 있다.0.01 to 50% (w / w) of the total weight, preferably 1 to 30% (w / w) when the new compound of the present invention or a salt thereof is included in a food additive or a health functional food in the form of a colored potato extract If the content is less than the above range, the effect obtained due to the expression of antioxidant activity will be insignificant. If the content is more than the above range, the synergistic effect due to the excess input is small and it is not economical. have.
즉, 통상적인 기호성 식품 즉, 라면, 생면 등의 면류, 두부, 시리얼, 빵류, 츄잉 껌, 사탕, 과자류 중에 첨가하여 통상적으로 알려진 방법에 의하여 각종 식품을 제조할 수 있고, 또한, 정제, 과립제, 환제, 경질캅셀제, 연질캅셀제 또는 액제 제형 등 일반적인 제형으로 제형화 될 수 있으며, 생즙, 파우치, 음료, 또는 다류로 제조될 수 있고, 상기한 성분 이외에 다른 성분은 제형에 따라 당업자가 적의 하게 선택하여 배합할 수 있다.That is, various foods can be prepared by a conventionally known method by adding them in conventional palates such as noodles, tofu, cereals, breads, chewing gum, candy, confectionary, such as ramen noodles, raw noodles, tablets, granules, It may be formulated into a general formulation such as pills, hard capsules, soft capsules, or liquid formulations, and may be prepared as a juice, pouch, beverage, or a variety of ingredients. Other ingredients than the above components may be appropriately selected by those skilled in the art according to the dosage form. It can mix.
상기 신규화합물은 식용되는 유색감자로부터 분리된 것으로 인체에 독성이 없이 안정하며, 항산화활성 및 항암활성을 가진다.The new compound is isolated from edible colored potatoes and is stable without toxicity to the human body, and has antioxidant activity and anticancer activity.
즉, 본 발명의 신규화합물 페츄나닌 JY는 지질과산화 초기에 안정적인 지질과산화 저해활성을 나타내는 것을 확인할 수 있어 신규 항산화제로서의 효과를 기대할 수 있다.In other words, it can be confirmed that the novel compound pethunanin JY of the present invention exhibits stable lipid peroxidation inhibitory activity in the early stage of lipid peroxidation, and thus can be expected to be effective as a novel antioxidant.
또한 본 발명의 신규화합물 페츄나닌 JY는 암세포주에 대하여 높은 생육저해 활성을 나타내므로 신규 항암제로서의 효과를 기대할 수 있다.In addition, the novel compound pethunanin JY of the present invention exhibits high growth inhibitory activity against cancer cell lines, and thus can be expected to be effective as a novel anticancer agent.
특히, 본 발명의 신규화합물 페츄나닌 JY는 특정 암세포주에 대한 높은 항암활성을 나타낼 뿐만 아니라, 정상세포에는 크게 영향을 미치지 않기 때문에 항암제 로서의 활용 및 기존항암제의 안정성 확보를 위한 병용처리 안정제 및 치료효율을 높일 수 있는 상승제로 활용을 기대할 수 있다.In particular, the novel compound pethunanin JY of the present invention not only exhibits high anticancer activity against certain cancer cell lines, but also does not significantly affect normal cells, so that it can be used as an anticancer agent and the stability of combination treatment to stabilize the existing anticancer agent. It can be expected to be used as a synergist to raise the cost.
이하 실시예에 의거하여 본 발명을 구체적으로 설명하겠는 바, 다음 실시예에 의하여 본 발명이 한정되는 것은 아니다. Although the present invention will be described in detail with reference to the following Examples, the present invention is not limited by the following Examples.
실시예 1. 재료 및 방법Example 1. Materials and Methods
1) 기기 및 시약. 1) Instruments and Reagents.
유색감자 함유 안토시아닌(anthocyanin)의 추출을 위해 사용된 증류수는 초순수 제조기(Milli-Q system, USA)에서 비저항값이 18 MΩ 이상으로 제조된 초순수 증류수를 사용하였고, 메탄올(methanol)은 국산 GR 등급을, 염산용액은 일본 화광순약주식회사의 특급시약을 구입하여 사용하였으며, Preparative-HPLC 및 Analytical-HPLC의 이동상 용매로 사용된 아세토니트릴(acetonitrile) 및 포믹산(formic acid)은 Merck Inc. (USA)의 HPLC 등급을 구입하여 사용하였다.Distilled water used for extraction of anthocyanin containing colored potatoes was made from ultrapure distilled water with a specific resistance of 18 MΩ or more in an ultrapure water maker (Milli-Q system, USA), and methanol (methanol) used a domestic GR grade. The hydrochloric acid solution was purchased from Japan Hwagwang Pure Chemical Co., Ltd., and the acetonitrile and formic acid used as mobile phase solvents of Preparative-HPLC and Analytical-HPLC were Merck Inc. HPLC grade (USA) was purchased and used.
안토시아닌 분리를 위한 칼럼 크로마토그래피(column chromatography)용 옥타데실실리카겔(Octadecylsilica gel, ODS)은 Lichroprep RP-18 (40~63 μm, Merck, Germany)을 사용하였고, 기기분석에 사용된 NMR용 용매는 메탄올-d4, Dcl(Merck, Germany)을 사용하였다. Octadecylsilica gel (ODS) for column chromatography for anthocyanin separation was used Lichroprep RP-18 (40-63 μm, Merck, Germany), and the solvent for NMR used in the instrument analysis was methanol -d4, Dcl (Merck, Germany) was used.
유색감자 함유 안토시아닌의 고순도 분리 및 정성분석에 사용된 Preparative-HPLC 및 Analytical-HPLC는 Agillent 1200 series (Agillent, Wilmington, DE, USA)를 사용하였으며, HRFAB-MS는 JMS 700 (JEOL, Kyoto, Japan)를 사용하여 측정하였다. UV 스펙트로포토미터(spectrphotometer)는 Shimadzu UV-1601 (Shimadzu, Kyoto, Japan)를 사용하였고, 비선광도는 Polarimeter P-1020 (JASCO, Kyoto, Japan)를 사용하여 측정하였다. NMR은 400 MHz, Inova AS 400, FT-NMR spectrometer (Varian, CA, USA)로 측정하였다. Preparative-HPLC and Analytical-HPLC were used for high-purity separation and qualitative analysis of anthocyanins containing colored potatoes.Agillent 1200 series (Agillent, Wilmington, DE, USA) was used, and HRFAB-MS was JMS 700 (JEOL, Kyoto, Japan). Measured using. UV spectrophotometer was used for Shimadzu UV-1601 (Shimadzu, Kyoto, Japan), and the non-luminescence was measured using Polarimeter P-1020 (JASCO, Kyoto, Japan). NMR was measured with a 400 MHz, Inova AS 400, FT-NMR spectrometer (Varian, CA, USA).
2) 실험재료.2) Experimental materials.
본 발명에 사용한 유색감자는 농촌진흥청에서 품종 등록한 자영품종(Solanum tuberosum L. cv Jayoung)으로서 2008년 4월 농촌진흥청 국립식량과학원 고령지농업연구센터에서 감자 표준재배법으로 재배된 감자(KNU-HMRAL-20080612)를 이용하여 실험을 진행하였다.The colored potato used in the present invention was a solanum tuberosum L. cv Jayoung, a variety registered by the Rural Development Administration (KNU-HMRAL-20080612). ) Was used to perform the experiment.
실시예 2. 신규 화합물의 분리. Example 2. Isolation of New Compounds.
유색감자 자영의 껍질을 제거하고 약 2-3 mm 정도로 절개 한 생체 1 kg을 1% 염산 함유-메탄올(20 L)을 상온에서 24시간 추출하였다. 얻어진 추출물을 여과하고, 남은 것은 동일한 방법으로 2회 더 추출하였다. 얻어진 여액을 모두 합치고 40℃ 조건에서 감압 농축하여 농축액을 얻었다. The skin of the colored potato Jayoung was removed and 1 kg of the living body incised about 2-3 mm was extracted with 1% hydrochloric acid-methanol (20 L) at room temperature for 24 hours. The obtained extract was filtered and the remaining one was extracted twice more in the same manner. The obtained filtrates were combined and concentrated under reduced pressure at 40 ° C to obtain a concentrated solution.
얻어진 1% 염산 함유-메탄올 농축액 중 100 mL를 분취하여 다시 감압 농축하고 남은 농축물에 1%염산 함유-증류수 100 mL를 첨가하여 ODS 칼럼 크로마토그래 피(φ 5 × 50 cm, 1%염산 함유 H2O : MeOH = 9 : 1 → 8 : 2 → 7 : 3 → 6 : 4 → 5 : 5 → 4 : 6으로 순차 분리)를 실시하여 5개의 분획(StJ-1~StJ-5)을 얻었고, 이중에서 주요 안토시아닌(major anthocyanin)으로 함유되어 있는 StJ-3 분획을 다시 40℃ 조건의 감압농축기에서 농축 건조한 후 1%염산 함유-20% 메탄올(50 mL)에 용해 한 후 Preparative-HPLC로 고순도 분리를 실시하여 prep 한 결과 화합물 1 (19 mg)을 순수 분리하였다[도 1]. 100 mL of the obtained 1% hydrochloric acid-methanol concentrate was collected, concentrated under reduced pressure again, and 100 mL of 1% hydrochloric acid-distilled water was added to the remaining concentrate, followed by ODS column chromatography (
이때, Preparative-HPLC의 분리 조건으로 사용된 prep 칼럼은 HiQ sil C18-10 (21.0 × 250 mm, KYA TECH, Japan)을 이용하였고, 분석파장 530 nm, 분당 유속 10 mL, 분석 용매로 A용매는 5% 포믹산 함유 증류수, B용매는 5% 포믹산함유 아세토니트릴을 (0분 : 85% A, 15분 : 85% A, 20분 : 70% A, 21분 : 85% A, 30분 : 85% A의) 사용하였고, 시료 주입량은 2 mL로 조절하여 고순도 분리를 실시하였다.At this time, the prep column used as a separation condition of Preparative-HPLC was used HiQ sil C18-10 (21.0 × 250 mm, KYA TECH, Japan), the analysis wavelength 530 nm,
화합물 1 : red amorphous powder; [α]25 D = -24.0° (c=0.10, MeOH); UV (MeOH) λmax 527 nm; pos. FAB-MS m/z: 1110 [M+H]+, 933 [M-feruloly+H]+, 787 [M-coumaroyl+H]+, 641 [M-rhamnose+H]+, 479 [M-glucose+H]+; 1H-NMR (400 MHz): 8.89 (1H, s, H-4), 7.86 (1H, d, 2.0 Hz, H-2'), 7.70 (1H, d, 2.0 Hz, H-6'), 7.50 (1H, d, 16.0 Hz, H-7f), 7.48 (1H, d, 16.0 Hz, H-7p), 7.37 (2H, d, 7.8 Hz, H-2p, 6p), 7.01 (1H, d, 1.6 Hz, H-2f), 6.99 (1H, br s, H-8), 6.96 (1H, br s, H-6), 6.91 (1H, dd, 7.4, 1.6 Hz, H-6f), 6.78 (1H, 7.8 Hz, H-3p, 5p), 6.75 (1H, d, 7.4 Hz, H-5f), 6.19 (1H, d, 16.0 Hz, H-8f), 6.17 (1H, d, 16.0 Hz, H-8p), 5.62 (1H, d, 8.0 Hz, H-1''), 5.27 (1H, dd, 8.0, 8.0 Hz, H-4'''), 5.24 (1H, d, 8.8 Hz, H-1'''), 4.88 (1H, dd, 9.5, 9.5 Hz, H-4''''), 4.72 (1H, br s, H-1''''), 4.05 (1H, br d, 11.0 Hz, H-6''a), 3.93 (3H, s, petunidin-OCH3), 3.78 (1H, br d, 11.0 Hz, H-6''b), 3.90~3.50 (sugar moiety), 3.39 (3H, s, feruloyl-OCH3), 0.97 (3H, d, 6.4 Hz, H-6''''); 13C-NMR (100 MHz): 169.5 (C-9p), 168.9 (C-9f), 168.2 (C-7), 163.6 (C-4p), 161.2 (C-2), 156.7 (C-5), 156.4 (C-9), 149.6 (C-3'), 147.4 (C-4'), 147.1 (C-5'), 146.9 (C-f4). 146.7 (C-7f, 7p), 146.0 (C-3), 133.9 (C-4), 131.2 (C-2p, 6p), 127.5 (C-3f), 127.0 (C-1p), 122.9 (C-6f), 119.5 (C-1'), 116.8 (C-3p, 5p), 116.5 (C-5f), 115.1 (C-2f), 115.0 (C-8p, 8f), 114.9 (C-1f), 113.8 (C-6'), 112.9 (C-10), 109.4 (C-2'), 105.4 (C-6), 102.5 (C-1''), 102.2, (C-1'''), 102.1 (C-1''''), 97.4 (C-8), 78.5 (C-5'''), 78.1 (C-5''), 77.7 (C-3'''), 77.5 (C-3''), 75.2 (C-4''''), 74.7 (C-2'', 2'''), 72.0 (C-4'''), 71.9 (C-3''''), 70.8 (C-4''), 70.2 (C-2''''), 67.7 (C-5''''), 67.2 (C-6''), 62.0 (C-6'''), 57.1 (petunidin-OCH3), 49.8 (feruloyl-OCH3), 17.8 (C-6'''')Compound 1: red amorphous powder; [a] 25 D = -24.0 ° (c = 0.10, MeOH); UV (MeOH) λ max 527 nm; pos. FAB-MS m / z: 1110 [M + H] + , 933 [M-feruloly + H] + , 787 [M-coumaroyl + H] + , 641 [M-rhamnose + H] + , 479 [M-glucose + H] +; 1 H-NMR (400 MHz): 8.89 (1 H, s, H-4), 7.86 (1 H, d, 2.0 Hz, H-2 '), 7.70 (1 H, d, 2.0 Hz, H-6'), 7.50 (1H, d, 16.0 Hz, H-7f), 7.48 (1H, d, 16.0 Hz, H-7p), 7.37 (2H, d, 7.8 Hz, H-2p, 6p), 7.01 (1H, d, 1.6 Hz, H-2f), 6.99 (1H, br s, H-8), 6.96 (1H, br s, H-6), 6.91 (1H, dd, 7.4, 1.6 Hz, H-6f), 6.78 (1H , 7.8 Hz, H-3p, 5p), 6.75 (1H, d, 7.4 Hz, H-5f), 6.19 (1H, d, 16.0 Hz, H-8f), 6.17 (1H, d, 16.0 Hz, H- 8p), 5.62 (1H, d, 8.0 Hz, H-1``), 5.27 (1H, dd, 8.0, 8.0 Hz, H-4 '''), 5.24 (1H, d, 8.8 Hz, H-1 '''), 4.88 (1H, dd, 9.5, 9.5 Hz, H-4``''), 4.72 (1H, br s, H-1''''), 4.05 (1H, br d, 11.0 Hz , H-6''a), 3.93 (3H, s, petunidin-OCH3), 3.78 (1H, br d, 11.0 Hz, H-6''b), 3.90-3.50 (sugar moiety), 3.39 (3H, s, feruloyl-OCH 3), 0.97 (3H, d, 6.4 Hz, H-6`` ''); 13C-NMR (100 MHz): 169.5 (C-9p), 168.9 (C-9f), 168.2 (C-7), 163.6 (C-4p), 161.2 (C-2), 156.7 (C-5), 156.4 (C-9), 149.6 (C-3 '), 147.4 (C-4'), 147.1 (C-5 '), 146.9 (C-f4). 146.7 (C-7f, 7p), 146.0 (C-3), 133.9 (C-4), 131.2 (C-2p, 6p), 127.5 (C-3f), 127.0 (C-1p), 122.9 (C- 6f), 119.5 (C-1 '), 116.8 (C-3p, 5p), 116.5 (C-5f), 115.1 (C-2f), 115.0 (C-8p, 8f), 114.9 (C-1f), 113.8 (C-6 '), 112.9 (C-10), 109.4 (C-2'), 105.4 (C-6), 102.5 (C-1 ''), 102.2, (C-1 '''), 102.1 (C-1`` ''), 97.4 (C-8), 78.5 (C-5 '''), 78.1 (C-5''), 77.7 (C-3'''), 77.5 (C -3 ''), 75.2 (C-4 ''''), 74.7 (C-2 '', 2 '''), 72.0 (C-4'''), 71.9 (C-3 '''' ), 70.8 (C-4``), 70.2 (C-2 ''''), 67.7 (C-5 ''''), 67.2 (C-6``), 62.0 (C-6 ''' ), 57.1 (petunidin-OCH 3 ), 49.8 (feruloyl-OCH 3 ), 17.8 (C-6`` '')
유색감자 자영의 1% 염산 함유-메탄올(methanol) 추출물을 ODS 칼럼 크로마토그래피 및 Preparative-HPLC 분리를 실시하여 1종의 신규 안토시아닌 화합물을 분리하였다.One novel anthocyanin compound was isolated by ODS column chromatography and preparative-HPLC separation of 1% hydrochloric acid-methanol extract of colored potato Ja-young.
화합물 1은 적색의 분말상으로써, TLC에 전개시켜 관찰한 결과 UV 흡수가 있었고, 10% aq. H2SO4로 분무, 건조 및 가열하였을 경우 진한 검붉은색으로 발색되었고, FAB-MS 스펙트럼으로부터 m/z: 1110 [M+H]+의 피크(peak)가 관측되었고, UV 스펙트럼(spectrum)으로부터 λmax 527 nm측정되어, 안토시아닌 화합물임을 예측할 수 있었다. IH-NMR (400MHz, CDCl3) 스펙트럼(spectrum)에서 δH 8.89 (1H, s, H-4), 7.86 (1H, d, 2.0 Hz, H-2'), 7.70 (1H, d, 2.0 Hz, H-6'), 6.99 (1H, br s, H-8) 및 6.96 (1H, br s, H-6)의 값으로부터 올레핀성 메틴 프로톤 시그널(olefinic methine proton signal)을 확인할 수 있었고, 각 시그널(signal)의 커플링 패턴(coupling pattern)으로부터 A-ring의 1,2,3,5-4치환 및 B-ring의 1,3,4,5-4치환된 시아니딘(cyanidin)의 구조임을 예상할 수 있었다. δH 5.62 (1H, d, 8.0 Hz, H-1''), 5.24 (1H, d, 8.8 Hz, H-1'''), 4.72 (1H, br s, H-1'''')의 시그널에서 당 분자들의 아노머 프로톤(anomer proton)이 관측 되었고, 세 개의 당 분자가 존재함을 예상하였다. 산소가 치환된 영역에서 다수의 산소화 메틴(oxygenated methine), 메틸렌 프로톤 시그널(methylene proton signal) (δH 3.90~3.50, sugar moiety)들이 관측되었고, 메톡시 시그널(methoxy signal) (δH 3.93, petunidin-OCH3 및 δH 3.39, feruloyl-OCH3)이 두 개 관측되었다. 또한, 아로마틱(aromatic) 영역에서 올레핀 메틴 시그널(olefine methine signal) [δH 7.50 (1H, d, 16.0 Hz, H-7f), 7.48 (1H, d, 16.0 Hz, H-7p), 7.37 (2H, d, 7.8 Hz, H-2p, 6p), 7.01 (1H, d, 1.6 Hz, H-2f), 6.91 (1H, dd, 7.4, 1.6 Hz, H-6f), 6.78 (1H, 7.8 Hz, H-3p, 5p), 6.75 (1H, d, 7.4 Hz, H-5f), 6.19 (1H, d, 16.0 Hz, H-8f), 6.17 (1H, d, 16.0 Hz, H-8p)]이 관측됨에 따라 두 개의 페놀산(phenolic acid)이 존재함을 예상하였다. 고자장 영역에서 메틸 프로톤 시그널(methyl proton signal) [δH 0.97 (d, 6.4 Hz, H-6'''')]이 관측 되었다. 13C-NMR 및 DEPT 스펙트럼(spectrum)에서 모두 53개의 시그널이 관측되었으며, 저자장 영역에서 카르보실 카본 시그널(carboxyl carbon signal) [δc 169.5 (C-9p), 168.9 (C-9f)]과 아그리콘(aglycone)의 올레핀 쿼터너리 카본 시그널(olefine quaternary carbon signal) [δc 168.2 (C-7), 161.2 (C-2), 156.7 (C-5), 156.4 (C-9), 149.6 (C-3'), 147.4 (C-4'), 147.1 (C-5'), 146.0 (C-3), 119.5 (C-1'), 112.9 (C-10)] 및 올레핀 메틴 카본 시그널(olefine methine carbon signal) [δc 133.9 (C-4), 113.8 (C-6'), 109.4 (C-2'), 105.4 (C-6), 97.4 (C-8)]이 관측되었다. 메톡시 시그널(Methoxy signal) [δc 57.1 (petunidin-OCH3)]이 HMBC 스펙트럼(spectrum)에서 아그리콘(aglycon)의 올레핀 쿼터너리 카본(olefine quaternary carbon) [δc 149.6 (C-3')]과의 크로스 피크(cross-peak)를 확인한 결과, 아그리콘(aglycone)은 페츄니딘(petunidin)으로 구조 동정하였다.
IH-NMR 스펙트럼(spectrum)에서 확인된 두 개의 페놀산(phenolic acid)의 프로톤 커플링 패턴(proton coupling pattern) 및 커플링(coupling) 값을 계산하고 동정된 시그널을 HSQC, HMBC 스펙트럼을 통하여 카본 시그널(carbon signal)을 동 정 한 결과, δc 168.9 (C-9f), 146.9 (C-4f), 146.7 (C-7f), 127.5 (C-3f), 122.9 (C-6f), 116.5 (C-5f), 115.1 (C-2f), 115.0 (C-8f), 114.9 (C-1f), 49.8 (feruloyl-OCH3)의 시그널은 페룰로일(feruloyl)로 구조 동정하였고, 올레핀 메틴 프로톤(olefin methine proton)(H-7f, H-8f)이 16.0 Hz로 커플링하는 것으로 미루어 트랜스(trans)임을 확인하였다. The proton coupling pattern and the coupling value of two phenolic acids identified in the IH-NMR spectrum are calculated, and the identified signals are carbon signals through the HSQC and HMBC spectra. As a result of identifying (carbon signal), δc 168.9 (C-9f), 146.9 (C-4f), 146.7 (C-7f), 127.5 (C-3f), 122.9 (C-6f), 116.5 (C- 5f), 115.1 (C-2f), 115.0 (C-8f), 114.9 (C-1f), 49.8 (feruloyl-OCH 3 ) signals were structurally identified as feruloyl and olefin methine protons (olefin) It was confirmed that the methine protons (H-7f, H-8f) were trans by coupling at 16.0 Hz.
나머지 다른 시그널을 동일한 방법으로 구조 동정한 결과, δc 169.5 (C-9p), 163.6 (C-4p), 146.7 (C-7p), 131.2 (C-2p, 6p), 127.0 (C-1p), 116.8 (C-3p, 5p), 115.0 (C-8p)의 시그널은 파라-쿠마로일(para-coumaroyl)로 구조 동정하였다. 아그리콘(aglycone)에 결합되어 있는 당 분자들의 아노머릭 프로톤 시그널(anomeric proton signal)을 토대로 COSY를 측정하고, 연결된 각 프로톤 시그널(proton signal)을 HSQC 스펙트럼을 바탕으로 카본 시그널(carbon signal)과 그로스 피크(cross-peak)를 확인한 결과, 아그리콘(aglycone)에 결합되어 있는 당은 글루코스(glucose) [(102.5 (C-1''), 78.1 (C-5''), 77.5 (C-3''), 74.7 (C-2''), 70.8 (C-4''), 67.2 (C-6''), (102.2, (C-1'''), 78.5 (C-5'''), 77.7 (C-3'''), 74.7 (2'''), 72.0 (C-4'''), 62.0 (C-6''')] 두 분자와 람노스(rhamnose) 한 분자 [102.1 (C-1''''), 75.2 (C-4''''), 71.9 (C-3''''), 70.2 (C-2''''), 67.7 (C-5''''), 17.8 (C-6'''')]들이 결합되어 있는 것을 확인하였다. HMBC 스펙트럼을 통해, 글루코스의 아노머릭 프로톤 시그널(anomeric proton signal) [δH 5.62 (d, 8.0 Hz, H-1'')] 과 아그리콘의 올레핀 쿼터너리 카본 시그널(olefine quaternary carbon signal) [δc 146.0 (C-3)]과 상호작용(correlation)하는 것이 확인 되었고, 산소화 메틸렌 시그널(oxygenated methylene signal) [δH 4.05 (1H, 11.0 Hz, H-6''a)] 이 람노스(rhamnose)의 아노머릭 카본(anomeric carbon) [102.1 (C-1'''')]과 결합되어 있으며, H-6’’a 시그널이 글리코시데이션 전이(glycosidation shift)에 의해 2 ppm 정도 저자장으로 이동함을 확인되었다. IH-NMR 및 13C-NMR 스펙트라(spectra) 에서 확인된 페놀산(phenolic acid), 파라-쿠마로일(para-coumaroyl)의 올레핀 메틴 프로톤(olefin methine proton)(H-7p, H-8p)이 16.0 Hz로, 트랜스(trans) 결합임을 확인하였다. 또한, 카르복실 카본(carboxyl carbon) [169.5 (C-9p)]가 람노스(rhamnose)의 산소화 메틴 프로톤(oxgenated methine proton) [δH 4.88 (dd, 9.5, 9.5 Hz, H-4'''')]과 상호작용(correlation)하는 것을 HMBC로 확인하였고, chemical shift로부터 아실화(acylated)된 것을 확인 하였다. HSQC로부터 연결되는 카본(carbon)이 δc 75.2 (C-4'''') 임을 확인하였고, 역시 약 2 ppm (일반적으로 73 ppm 정도의 값을 가짐)정도 저자장으로 전이(shift) 되는 것을 확인 하였다. 아글리콘 5번 카본(carbon)에는 또 다른 글루코스의 아노머릭 프로톤 시그널(anomeric proton signal) [δH 5.24 (d, 8.8 Hz, H-1''')]이 아그리콘의 올레핀 쿼터너리 카본 시그널[δc 156.7 (C-5)]과 상호작용(correlation)하는 것을 HMBC 스펙트럼(spectrum)으로 확인되었다. 페놀산(Phenolic acid), 페룰로일(feruloyl) 역시, 올레핀 메틴 프로톤(olefin methine proton)(H-7f, H-8f)이 16.0 Hz로, 트랜스(trans)임을 확인되었으며, 카르복실 카본(carboxyl carbon)[δc 168.9 (C-9f)]이 글루코스의 산소화 메틴 프로 톤(oxgenated methine proton)[δH 5.27 (1H, dd, 8.0, 8.0 Hz, H-4''')]과 상호작용하는 것을 HMBC 스펙트럼(spectrum)으로 확인하였고, HSQC 스펙트럼(spectrum)과 케미칼 전이(chemical shift), 커플링 패턴(coupling pattern) 등을 확인한 결과 글루코스의 4'''에 결합되어있는 것을 확인하였다. 동정된 화합물의 질량 값을 측정하기 위하여, FAB-MS (positive) 실험을 진행한 결과, [M+H] m/z : 1110 [M+H]+ 933 [M-feruloly+H]+, 787 [M-coumaroyl+H)+, 641 [M-rhamnose+H]+, 479 [M-glucose+H]의 값이 확인되었고, 측정한 질량 값 및 프래그멘테이션 패턴(pragmentation pattern)이 동정한 구조와 일치함을 보였다. As a result of structural identification of the other signals in the same manner, δc 169.5 (C-9p), 163.6 (C-4p), 146.7 (C-7p), 131.2 (C-2p, 6p), 127.0 (C-1p), The signals of 116.8 (C-3p, 5p) and 115.0 (C-8p) were structurally identified as para-coumaroyl. COSY is measured based on the anmeric proton signal of sugar molecules bound to aglycone, and each connected proton signal is carbon signal and gross based on HSQC spectrum. As a result of the cross-peak, the sugar bound to the aglycone contained glucose [(102.5 (C-1``), 78.1 (C-5 ''), 77.5 (C-3). ''), 74.7 (C-2``), 70.8 (C-4 ''), 67.2 (C-6 ''), (102.2, (C-1 '' '), 78.5 (C-5' ' '), 77.7 (C-3' ''), 74.7 (2 '' '), 72.0 (C-4' ''), 62.0 (C-6 '' ')]. Two molecules and one rhamnose. Molecules [102.1 (C-1 '' ''), 75.2 (C-4 '' ''), 71.9 (C-3 '' ''), 70.2 (C-2 '' ''), 67.7 (C- 5 '' ''), 17.8 (C-6 '' '')]. The HMBC spectra show glucose's anmeric proton signal [δH 5.62 (d, 8.0 Hz). , H-1 '')] and Oglycone's olefin quaternary carbon signal Correlation with [δc 146.0 (C-3)] was confirmed, and oxygenated methylene signal [δH 4.05 (1H, 11.0 Hz, H-6``a)] rhamnose ) Is combined with the anmeric carbon [102.1 (C-1 '' '')] and the H-6''a signal is reduced to about 2 ppm by glycosidation shift. Olefin methine protons of phenolic acid, para-coumaroyl identified in IH-NMR and 13C-NMR spectra (H-7p) , H-8p) was found to be a trans bond at 16.0 Hz. In addition, carboxyl carbon [169.5 (C-9p)] was used as the oxygenated methine proton of rhamnose [δH 4.88 (dd, 9.5, 9.5 Hz, H-4 '' ''. )] And the interaction (correlation) was confirmed by HMBC, it was confirmed that the acylated (acylated) from the chemical shift. It was confirmed that the carbon connected from HSQC was δc 75.2 (C-4`` '') and also shifted to about 2 ppm (typically around 73 ppm) to the low field. It was.
상기한 바를 종합하여 구조 동정한 결과, 유색감자 자영에서 추출하여 분리된 신규 화합물은 petunidin-3-O-[6-O-(4-O-E-p-coumaroyl-α-L-rhamnopyranosyl)-β-D-glucopyranosyl]-5-O-(4-O-E-feruloyl)-β-D-glucopyranoside 임을 확인하였으며, 이는 현재까지 보고되지 않은 신규 화합물로 판명되었다[도 1 참고].A general structure identified by the above-described bar results, the novel compounds isolated by extraction from the colored potato is independent petunidin-3- O - [6- O - (4-O- Ep -coumaroyl- α-L -rhamnopyranosyl) - β- D- glucopyranosyl] -5 -O- (4- OE- feruloyl) -β -D -glucopyranoside was identified, which turned out to be a novel compound that has not been reported to date [see Figure 1].
본 출원인은 상기한 신규 화합물을 페츄나닌(Petunanin) JY으로 명명하였으며, 화학식 1에 구조를 나타내었다.The Applicant named the novel compound Petunanin JY, and shows the structure in
실험예. 신규화합물 페츄나닌(Petunanin) JY의 특성Experimental Example Characteristics of New Compound Petunanin JY
1) 신규화합물 페츄나닌 JY의 항산화 활성 검정 1) Antioxidant Activity Assay of Novel Compound Pethunanin JY
신규화합물 페츄나닌 JY의 항산화 활성 검정은 Nagai 등에 의한 방법을 사용하여 측정하였다. Antioxidant activity assay of the novel compound pethunanin JY was measured using the method by Nagai et al.
농도별로 제조된 페츄나닌 JY 0.083mL에 0.208mL의 소듐 포스페이트 완충 액(sodium phosphate buffer)(pH 7.0)을 혼합하고 다시 0.208mL의 2.5%(w/v) 리놀산(linoleic acid)을 첨가하였다. 산화 유도 시작은 0.021mL의 0.1M 2,2'-azobis (2-amidinopropane) dihydrochloride를 첨가하여 37°C, 암상태로 반응시키면서부터 시작하여 200분까지 매 50분마다 리놀산이 산화되는 정도를 검정하였다. 0.208 mL of sodium phosphate buffer (pH 7.0) was mixed with 0.083 mL of pethunanin JY prepared for each concentration, and 0.208 mL of 2.5% (w / v) linoleic acid was added again. Oxidation induction was initiated by adding 0.021 mL of 0.1M 2,2'-azobis (2-amidinopropane) dihydrochloride to reaction at 37 ° C in the dark, and then oxidizing linoleic acid every 50 minutes up to 200 minutes. It was.
상기 기술한 반응액 0.1 mL에 75% 에탄올 4.7mL, 30% 암모늄 티오시아네이트(ammonium thiocyanate) 0.1mL, 3.5% HCl이 포함된 0.02M 염화 제1철(ferrous chloride) 0.1mL를 혼합한 후에 3분 동안 정치하여 두었다가 UV-1200 UV/VIS 스펙트로미터(spectrometer)(Shimadzu, Kyoto, Japan)를 사용하여 과산화물 생성정도를 500nm에서 흡광도로 측정하였다. 대조구는 시료를 첨가하지 않고 리놀산만을 첨가한 것을 사용하였다. 항산화 활성평가의 대조구는 토코페롤(α-tocopherol)(VE)과 아스코르브산(ascorbic acid)(VC)를 100ppm 수준으로 제조하여 사용하였다. 200분 후에 최종 저해율(%)을 농도별로 산출하였다[도 2 및 도 3]. 0.1 mL of the reaction solution described above was mixed with 4.7 mL of 75% ethanol, 0.1 mL of 30% ammonium thiocyanate, and 0.1 mL of 0.02M ferrous chloride containing 3.5% HCl. After standing for a minute, peroxide production was measured by absorbance at 500 nm using a UV-1200 UV / VIS spectrometer (Shimadzu, Kyoto, Japan). As a control, only linoleic acid was added without adding a sample. As a control of antioxidant activity evaluation, tocopherol (α-tocopherol) (VE) and ascorbic acid (VC) were prepared using 100 ppm level. Final inhibition rate (%) was calculated for each concentration after 200 minutes [FIGS. 2 and 3].
신규 화합물 페츄나닌 JY의 리놀산 과산화 초기 단계에서의 항산화 활성을 검정하여 본 결과 페츄나닌 JY의 최종 농도 10ppm과 25ppm으로 처리되어진 경우 아스코르브산과 토코페롤(α-tocopherol) 100ppm 수준으로 처리한 대조군 보다 낮은 활성을 나타내었으나, 50ppm 이상의 경우 아스코르브산과 토코페롤보다 높은 저해활성을 나타내었다. 아스코르브산과 토코페롤이 100분 이후에 저해활성이 낮아지는 경향을 나타내는 반면 페츄나닌 JY의 경우 반응초기부터 150분까지 활성이 유지되는 결과를 나타내었다. Assay of antioxidant activity in the early stage of linoleic acid peroxidation of the novel compound petuninin JY showed lower activity than the control treated with 100 ppm of ascorbic acid and tocopherol when treated with 10 ppm and 25 ppm final concentrations of petuninin JY. In the case of 50 ppm or more, ascorbic acid and tocopherol showed higher inhibitory activity. Ascorbic acid and tocopherol showed a tendency to lower the inhibitory activity after 100 minutes, whereas in the case of pethunanin JY, the activity was maintained from the initial reaction to 150 minutes.
따라서 아스코르브산이나 토코페롤과 같은 경우 지질과산화 저해활성 유도하는데 있어 반응시간이 경과함에 따라 산화된 형태로 변화하고 저해활성이 낮아지는 반면 페츄나닌 JY의 경우 50ppm 이상의 농도로 처리하는 경우 지질과산화 초기에 안정적인 지질과산화 저해활성을 나타내는 것을 확인할 수 있어 신규 항산화제로서의 역할이 기대된다.Therefore, in the case of ascorbic acid or tocopherol, induction of lipid peroxidation inhibiting activity is changed to oxidized form and the inhibitory activity is lowered as the reaction time elapses. It can be confirmed that it exhibits lipid peroxidation inhibitory activity and is expected to play a role as a novel antioxidant.
2) 신규화합물 페츄나닌(Petunanin) JY의 DPPH 라디칼 소거활성 검정 2) DPPH Radical Scavenging Activity of the New Compound, Petunanin JY
신규화합물 페츄나닌 JY의 DPPH 라디칼(radical) 소거활성 검정은 Okada and Okada 등에 의한 방법을 변형하여 측정하였다. 0.1mL의 1.0mM DPPH 라디칼 용액(radical solution)에 0.8mL의 99% 에탄올(ethanol)과 페츄나닌 JY의 농도별 시료 0.1mL를 첨가 혼합하고 암상태에서 30분동안 정치하여 둔 후 UV-1200 UV/VIS 스펙트로미터(Shimadzu, Kyoto, Japan)를 사용하여 517nm에서 흡광도로 측정하여 검정하였다. The DPPH radical scavenging activity assay of the novel compound pethunanin JY was measured by modifying the method by Okada and Okada et al. 0.1 mL of 1.0 mM DPPH radical solution was added and mixed with 0.8 mL of 99% ethanol and 0.1 mL of Pethunanin JY concentration sample, and left to stand for 30 minutes in the dark. UV-1200 UV Absorbance at 517 nm was measured using a / VIS spectrometer (Shimadzu, Kyoto, Japan) and assayed.
이때 기질과 DPPH가 없는 Initial(Ai), 과 blank(Ab)를 측정하였으며, 시료 첨가 후 흡광도(As)를 측정하였고, RC50(㎍/mL)은 화합물을 첨가하지 않은 대조군의 값을 50% 감소시키는 화합물의 농도를 나타냈으며, 기존의 항산화제인 토코페롤(VE) 및 아스코르브산(VC)과 상호 비교하였다.At this time, initial (Ai), blank (Ab) without substrate and DPPH were measured, and absorbance (As) was measured after sample addition. RC50 (㎍ / mL) decreased the value of control group without compound by 50%. The concentration of the compound was shown and compared with the existing antioxidants tocopherol (VE) and ascorbic acid (VC).
[표 1] 페츄나닌 JY 의 DPPH 유리 라디칼 소거활성(scavenging activity) Table 1: DPPH free radical scavenging activity of pethunanin JY
(RC50 ㎍/mL)DPPH radical scavenging activity
(RC 50 μg / mL)
1,1-디페닐-2-피크릴하이드라질(1,1-diphenyl-2-picrylhydrazyl, DPPH)을 이용하여 페츄나닌 JY의 자유라디칼 소거활성을 측정한 결과 RC50 값이 약 94㎍/mL을 나타내었다. 아스코르브산(Ascorbic acid)의 경우 RC50이 46.25㎍mL-1, 토코페롤(α-tocopherol) 은 92.13 ㎍mL-1으로 나타난 것과 비교하여 페츄나닌 JY의 라디칼 소거활성은 토코페롤과 유사하였다. Free radical scavenging activity of pethunanin JY using 1,1-diphenyl-2-picrylhydrazyl (DPPH) was measured and the RC 50 value was about 94 µg / mL. Indicated. In the case of ascorbic acid, the radical scavenging activity of pethunanin JY was similar to that of tocopherol compared to that of RC 50 of 46.25 μg mL −1 and tocopherol of 92.13 μg mL −1 .
페츄나닌 JY의 경우 지질과산화(lipid peroxidation) 저해활성이 라디칼 소거활성 보다 높은 결과를 볼 때 라디칼 형성을 직접적으로 막는 것 보다는 라디칼 사슬(radical chain)을 절단(breaking)하여 높은 항산화 효과를 나타내는 것으로 평가된다. In case of pethunanin JY, lipid peroxidation inhibitory activity is higher than radical scavenging activity, and it is evaluated that it shows high antioxidant effect by breaking the radical chain rather than directly blocking radical formation. do.
3) 신규화합물 페츄나닌 JY의 하이드록시 라디칼 소거 활성 검정 3) Hydroxy Radical Scavenging Activity Assay of Novel Compound Pethunanin JY
신규화합물 페츄나닌 JY의 하이드록시 라디칼(hydroxy radical) 소거 활성검정은 펜톤(Fenton) 반응에 의한 데옥시리보스(2-Deoxyribose)가 하이드록시 라디칼에 의해 산화되어 말론알데하이드(malonaldehyde)로 변환되어 크로마겐(chromagen)을 형성하는 정도를 측정하는 방법을 이용하였다. The hydroxy radical scavenging activity assay of the novel compound, pethunanin JY, is carried out by deoxyribose, which is oxidized by hydroxy radicals and converted to malonaldehyde, by the Fenton reaction. A method of measuring the degree of (chromagen) formation was used.
0.45mL의 0.2M 소듐 포스페이트 완충액(sodium phosphate buffer)(pH 7.0), 0.15mL의 10mM 2-deoxyribose, 0.15mL의 10 mM FeSO4EDTA, 0.15mL의 10mM H2O2, 0.525mL의 H2O, 그리고 0.075mL의 페츄나닌 JY 농도별 시료를 에펜도르프 튜브(Eppendorf tube)에 넣고 37°C, 암상태로 4시간 동안 반응시킨 후 0.75mL의 2.8%(w/v) 트리클로로아세트산(trichloroacetic acid)과 0.75mL의 1.0%(w/v) TBA를 넣어 반응을 종결하였다. 반응액을 끓는 물에 10분 동안 처리한 후 상온에서 냉각시키고 UV-1200 UV/VIS 스펙트로미터(spectrometer)(Shimadzu, Kyoto, Japan)를 사용하여 520nm에서 흡광도로 측정하여 검정하였다. 0.45 mL 0.2 M sodium phosphate buffer (pH 7.0), 0.15
하이드록시 라디칼 소거활성 검정은 페츄나닌 JY의 농도별 첨가에 따라 하이드록시 라디칼에 의해 데옥시리보스(2-deoxyribose)가 산화되는 것을 저해하는 비율로 계산하였고 대조군은 시료 대신에 멸균수를 첨가하여 측정하였고, IC50(㎍/mL)은 페츄나닌 JY를 첨가하지 않은 대조군의 값을 50% 감소시키는 시료의 농도로 나타내었으며 기존의 항산화제인 토코페롤(VE) 및 아스코르브산(VC)과 상호 비교하였다. The hydroxy radical scavenging activity assay was calculated as the rate of inhibiting the oxidation of 2-deoxyribose by the hydroxy radical with the addition of pethunanin JY concentration, and the control was determined by adding sterile water instead of the sample. The IC 50 (μg / mL) was expressed as the concentration of the sample which reduced the value of the control group without the addition of petanin JY by 50%, and compared with the existing antioxidants tocopherol (VE) and ascorbic acid (VC).
[표 2] 페츄나닌 JY의 하이드록시 라디칼 소거활성(scavenging activity)Table 2: Hydroxy radical scavenging activity of pethunanin JY
(IC50 ㎍/mL) Hydroxyl radical scavenging activity
(IC 50 μg / mL)
하이드록시 라디칼(OH)은 활성산소 중 반응성이 매우 강하여 생체 산화에 주 된 역할을 하는 것으로 알려져 있다. 특히 하이드록시 라디칼은 DNA의 푸린(purine)과 피리미딘(pyrimidine) 염기를 무차별적으로 공격하여 다양하게 변형시킬 뿐만 아니라 데옥시리보스(2-deoxyribose) 부분을 공격하여 DNA사슬의 절단을 일으킨다. 암, 동맥경화증, 자가면역질환, 관절염, 폐질환, 당뇨병, 심근경색증, 뇌 및 신경질환 등의 발생과 진행경과에 자유 라디칼(free radical)이 관여하고 있다는 증거들이 많이 보고되고 있다. Hydroxy radicals (OH) are known to play a major role in biooxidation because they are very reactive in active oxygen. In particular, the hydroxy radicals indiscriminately attack the purine and pyrimidine bases of DNA, and variously modify them, as well as the deoxyribose moiety, which causes the cleavage of DNA chains. There is a lot of evidence that free radicals are involved in the development and progression of cancer, arteriosclerosis, autoimmune diseases, arthritis, lung diseases, diabetes, myocardial infarction, brain and neurological diseases.
따라서 신규 화합물 페츄나닌 JY가 항산화 효과에 기인하는 다양한 질병에 대한 예방과 치료에 적용되어질 수 있는가를 확인하기 위해 하이드록시 라디칼 소거활성을 검토한 결과 하이드록시 라디칼의 생성을 50% 저해하는 데 필요한 농도는 약 113.3㎍/mL로 나타나 대조구 활성물질인 토코페롤에는 미치지는 못하나 아스코르브산 보다는 월등하게 높은 하이드록시 라디칼 소거활성을 나타내었다. Therefore, the results of examining the hydroxy radical scavenging activity to confirm whether the novel compound pethunanin JY can be applied to the prevention and treatment of various diseases due to the antioxidant effect, the concentration required to inhibit the production of hydroxy radicals by 50% It was about 113.3 ㎍ / mL, which showed less hydroxy radical scavenging activity than ascorbic acid, although it did not reach the tocopherol control.
4) 신규화합물 페츄나닌 JY의 수퍼옥사이드(superoxide) 소거활성 측정4) Determination of Superoxide Scavenging Activity of the New Compound Pethunanin JY
신규화합물 페츄나닌 JY의 수퍼옥사이드 라디칼(superoxide radicals) 소거활성은 NBT(nitro-blue tetrazolium)환원법을 사용하여 검정하였다. The superoxide radicals scavenging activity of the novel compound pethunanin JY was assayed using nitro-blue tetrazolium (NBT) reduction method.
즉, 3mM xanthine 0.02mL, 0.05mM sodium carbonate buffer(pH 10.5) 0.48mL, 3mM EDTA(ethylenediaminetetraacetic acid disodium salt) 0.02mL와 0.15% 송아지 혈청 알부민(bovine serum albumin) 0.02mL, 0.75mM NBT 0.02mL로 구성된 혼합액에 페츄나닌 JY를 10, 25, 50, 100㎍/mL의 농도로 각각 처리하였으며, 이 혼합물을 25℃에서 10분간 incubation 하였으며, 다시 1.0mL의 XOD(6mU/mL)를 첨가하여 반응을 시작한 후 25℃에서 20분간 반응하였다. 그 후 0.02mL의 6mM CuCl를 첨가하여 반응을 종결시킨 후 560nm에서 흡광도를 측정하였다. 농도별 시료 첨가 양에 따른 NBT환원에 대한 저해능을 50% 감소시키는 화합물의 농도(IC50, 50% inhibition concentration)를 나타냈으며, 카테킨((+)-catechin), 알로푸린올(allopurinol)(Sigma), 아스코르빈산(VC)을 대조구로 사용하여 비교하였다. It consists of 0.02 mL of 3 mM xanthine, 0.48 mL of 0.05 mM sodium carbonate buffer (pH 10.5), 0.02 mL of 3 mM ethylenediaminetetraacetic acid disodium salt (EDTA), 0.02 mL of 0.15% bovine serum albumin, and 0.02 mL of 0.75 mM NBT. Pethunanine JY was treated at 10, 25, 50, and 100 ㎍ / mL, respectively, and the mixture was incubated at 25 ° C for 10 minutes. Then, 1.0 mL of XOD (6mU / mL) was added to start the reaction. After reacting for 20 minutes at 25 ℃. Thereafter, 0.02 mL of 6 mM CuCl was added to terminate the reaction, and the absorbance was measured at 560 nm. The concentration of the compound (IC 50 , 50% inhibition concentration) was shown to reduce the inhibitory activity against NBT reduction by 50% according to the amount of sample added by concentration, catechin ((+)-catechin) and allopurinol (Sigma). ), Ascorbic acid (VC) was used as a control.
[표 3] 페츄나닌 JY의 수퍼옥사이드 음이온 라디칼의 억제 효과[Table 3] Inhibitory effect of superoxide anion radicals of pethunanin JY
inhibition activity
(IC50 ㎍/mL) Xanthine oxidase
inhibition activity
(IC 50 μg / mL)
페츄나닌 JY의 쟌틴 옥시다제(xanthine oxidase) 활성억제를 측정한 결과 수퍼옥사이드 소거활성에 대한 IC50 값이 하이드록시기(hydrxyl group)를 다량으로 함유하고 있는 알로푸린올과 카테킨이 각각 3.45㎍/mL와 7.2㎍/mL를 나타낸 반면 페츄나닌 JY의 경우 23.7㎍/mL를 나타내어 다소 낮은 활성을 나타내었으나, 아스코르브산 보다 우수한 양상을 나타내었다. Inhibition of xanthine oxidase activity of petuninin JY showed that IC 50 values for superoxide scavenging activity were 3.45 ㎍ / a for allopurinol and catechin, each containing a large amount of hydroxy group. While mL and 7.2 μg / mL were shown, petuninin JY showed 23.7 μg / mL, which showed somewhat lower activity, but showed a better aspect than ascorbic acid.
상기한 결과는 각 화합물이 포함하고 있는 하이드록시기의 양적 차이에 기인하는 것으로 사료되며, 페츄나닌 JY의 경우 높은 항산화 효과와 함께 쟌틴 옥시다제 저해활성을 나타냄을 알 수 있다. 쟌틴 옥시다제 저해제는 통풍, 신장결석, 허혈, 심근증을 일으키는 요산혈증(hyperuricemia)에 대한 치료제로 사용되어 왔으며, 현대와 같은 고령화 시대를 대비한 저해제 개발이 절실히 요구되어지고 있다. The above results are believed to be due to the quantitative difference of the hydroxyl groups contained in each compound, it can be seen that the pethunanin JY shows a high activity of antioxidant and quentin oxidase inhibitory activity. Quentin oxidase inhibitors have been used as a treatment for hyperuricemia causing gout, kidney stones, ischemia and cardiomyopathy, and there is an urgent need for developing inhibitors for the aging age.
이에 페츄나닌 JY와 같은 유색감자와 그 유용산물인 안토시아닌을 산업 및 약용적 활용에 적용한다면 여러 가지 다양한 질병들을 치료하고 예방할 수 있는 안전하고 효과적인 건강기능성 소재로 활용할 수 있을 것으로 사료된다.Therefore, if the colored potato such as pethunanin JY and its useful product, anthocyanin, are applied to industrial and medicinal applications, it can be used as a safe and effective health functional material that can cure and prevent various diseases.
5) 신규화합물 페츄나닌 JY의 항암활성 및 정상세포에 대한 독성평가5) Anticancer Activity and Toxicity Assessment of Normal Cells
페츄나닌 JY의 인체 암세포주에 대한 세포생육억제 효과를 SRB(Sulfo Rhodamine B)법으로 조사하였다. 암세포주는 전립선암 세포주인 LNCaP, 결장암 세포주인 HCT-15, 위암 세포주인 ACHN, 폐암 세포주인 A549, 백혈병 세포주인 MOLT-4F를 사용하였다. Inhibition of cell growth inhibition of the human cancer cell line by pethunanin JY by SRB (Sulfo Rhodamine B) method. The cancer cell line was a prostate cancer cell line LNCaP, colon cancer cell line HCT-15, gastric cancer cell line ACHN, lung cancer cell line A549, leukemia cell line MOLT-4F was used.
정상세포에 대한 독성을 확인하기 위하여 간세포주인 293(human embryo liver)을 한국세포주은행(Korea Cell Line Bank, KCLB)로부터 구입하여 대조구로 사용하였다. 상기 암세포주는 10% 소 태아 혈청이 포함된 RPMI 1640배지를 사용하여 배양하였고, 배양된 세포는 일주일에 한 번 또는 두 번 정도 분주하여 유지하였다. To confirm the toxicity to normal cells, hepatocyte line 293 (human embryo liver) was purchased from Korea Cell Line Bank (KCLB) and used as a control. The cancer cell line was cultured using RPMI 1640 medium containing 10% fetal bovine serum, and cultured cells were maintained by dispensing once or twice a week.
항암활성을 측정하는데 사용하는 세포농도는 3,000~6,000개/mL이었으며, 상기 방법에 사용한 모든 시약은 100% DMSO에 녹이고, 이를 단계적으로 희석하여 페츄나닌 JY의 농도를 30, 10, 5, 2.5, 1, 0.1㎍/mL로 조제하였다. 세포의 수를 측정하여 일정한 농도로 96-웰 플레이트(well plate)에 분주하고 하루가 경과한 다음 세포가 나타내는 기본적인 흡광도를 나타내는데 필요한 Tz 플레이트(plate)로서 시료를 처리할 플레이트와 동일한 세포농도를 가진 다른 플레이트를 50% TCA를 사용 하여 고정하였다. 그리고 시료를 처리할 플레이트는 시료의 최종 농도를 0.1% DMSO로 맞추어 5개의 농도로 처리하였다. Tz 플레이트(plate)는 1시간이 경과하면 수돗물로 세척하고, 시료를 처리한 플레이트는 2일이 경과한 다음 50% TCA를 well당 50μL씩 처리하여 고정하고 역시 1시간이 경과하면 수돗물로 세척하였다. 세척한 플레이트는 상온에서 건조시키고, 그 후 0.4% SRB 용액을 well 당 100μL씩 가한 다음 30분이 경과하면 1% 아세트산 용액으로 세척하였고, 이를 다시 상온에서 건조 시켰다. 다음 10mM Tris 염기(pH: 10.5)를 well 당 100μL씩 가하여 다시 용해시키고, ELISA 해독기를 사용하여 540nm 에서 흡광도를 측정하였다. 이 때 암세포의 성장을 50% 억제하는 화합물의 농도를 GI50(㎍/mL)으로 나타내었고, 대조군으로 아드리아미신(adriamycin)을 사용하였다.The cell concentration used for measuring anticancer activity was 3,000 to 6,000 cells / mL, and all the reagents used in the above method were dissolved in 100% DMSO, and diluted in stages to reduce the concentration of petuninan JY to 30, 10, 5, 2.5, 1, 0.1 µg / mL was prepared. The Tz plate is required to measure the number of cells, divide them into 96-well plates at a constant concentration, and display the basic absorbance of the cells after one day, with the same cell concentration as the plate to be treated. The other plate was fixed using 50% TCA. The plate to be treated with the sample was treated with five concentrations by adjusting the final concentration of the sample to 0.1% DMSO. The Tz plate was washed with tap water after 1 hour, and the plate treated with the sample was fixed with 50 μL of 50% TCA per well after 2 days, and washed with tap water after 1 hour. . The washed plate was dried at room temperature, and then 0.4 μl SRB solution was added to 100 μL per well, and then washed with 1% acetic acid solution after 30 minutes, and dried again at room temperature. Then, 10 mM Tris base (pH: 10.5) was added to 100 μL per well to dissolve again, and the absorbance was measured at 540 nm using an ELISA reader. At this time, the concentration of the compound that inhibits the growth of cancer cells by 50% was expressed as GI 50 (µg / mL), and adriamycin was used as a control.
[표 4] 페츄나닌 JY의 인체 암세포주에 대한 세포생육억제 활성[Table 4] Cell Growth Inhibition Activity of Human Cancer Cell Lines by Pethunanin JY
(HCT-15)Colon
(HCT-15)
(ACHN)Renal
(ACHN)
(SW-620)Colon
(SW-620)
(A549)Lung
(A549)
(MOLT-4F)Leukaemia
(MOLT-4F)
페츄나닌 JY의 인체 암세포주에 대한 세포생육억제 효과를 SRB법으로 검정하여 본 결과 폐암 세포주인 A549세포, 결장암세포주인 HCT-15 및 SW-620에서는 페츄나닌 JY가 활성을 나타내지 않은 반면에 전립선암 세포주인 LNCaP와 백혈병세포주 MOLT-4F에 대해서는 각각 GI50(㎍/mL)값이 17.64, 16.77㎍/mL로 나타나 우수한 세포 독성 효과를 나타내었고, 신장암세포주(ACHN)에 대해서도 약한 활성을 나타내었다. As a result of assaying the effect of petuninin JY on the growth of human cancer cell line by SRB method, prostate cancer was not found in lung cancer cell line A549 cell, colon cancer cell line HCT-15 and SW-620 while petuninin JY showed no activity. For cell lines LNCaP and leukemia cell line MOLT-4F, the GI 50 (µg / mL) values were 17.64 and 16.77 µg / mL, respectively, showing excellent cytotoxic effects and weak activity against renal cancer cell line (ACHN). .
페츄나닌 JY의 정상 간세포주인 293에 대한 독성여부를 확인하기 위하여 시료농도에 따른 증식 억제효과를 검토한 결과 100㎍/mL 첨가 시 암세포주에 대하여 대부분 60% 전후의 생육 억제율을 보이는데 반해 293세포에 대해서는 2% 이하의 생육 억제율을 나타내었다. In order to confirm the toxicity of pethunanin JY to normal liver cell line 293, we examined the inhibitory effect on the growth of sample according to the concentration of the sample. Inhibition of growth was less than 2%.
이는 페츄나닌 JY가 암세포주에 대한 높은 억제 효과를 나타내는 반면 정상세포에 대해서는 생육 억제효과가 거의 없는 것을 나타낸다고 할 수 있다. This can be said that the pethunanin JY shows a high inhibitory effect on cancer cell lines, but little growth inhibitory effect on normal cells.
최근 연구에 의하면 결장암에 대한 길항대사치료제인 5-Flurouracil(5-Fu) 투여 시 암세포뿐만 아니라 소장의 상피세포와 같이 급속하게 생장하는 정상세포를 손상 시키는 부작용을 막기 위하여 안토시아닌이 풍부하게 존재하는 추출물(50㎍/mL 이상)을 병용하여 처리하면 암세포의 성장억제 효율이 30% 상승될 뿐만 아니라 정상세포에 대한 부작용도 억제시킬 수 있으나 50㎍/mL 보다 낮은 농도에서는 크게 영향을 미치지 못한다고 보고되어진다. Recent studies have shown that anthocyanin-rich extracts contain 5-Flurouracil (5-Fu), an antagonist for colon cancer, to prevent side effects that damage normal cells, such as epithelial cells of the small intestine, as well as cancer cells. (50μg / mL or more) in combination not only increases the growth inhibition efficiency of cancer cells by 30% but also suppresses adverse effects on normal cells, but it is reported that it does not significantly affect concentrations below 50μg / mL. .
상기한 결과를 살펴보면, 신규화합물 페츄나닌 JY는 특이적 암세포주에 활성을 나타내는 것으로 생각되며, 특정 암세포주에 대한 높은 항암활성은 나타낼 뿐만 아니라, 정상세포에는 크게 영향을 미치지 않기 때문에 항암제로서의 활용 및 기존항암제의 안정성 확보를 위한 병용처리 안정제 및 치료효율을 높일 수 있는 상승제로 활용되어질 수 있을 것으로 판단된다. In view of the above results, it is thought that the novel compound pethunanin JY exhibits activity on specific cancer cell lines, and it shows high anticancer activity against specific cancer cell lines and does not significantly affect normal cells. It is expected to be used as a combination treatment stabilizer and a synergist to increase the treatment efficiency to secure the stability of existing anticancer drugs.
상기에서 확인된 바와 같이, 화학식 1로 표시되는 본 발명의 신규화합물 페 츄나닌 JY는 우수한 항산화 및 항암효과를 나타내므로 암에 대한 치료 및 예방용 약학적 조성물로 제제화될 수 있다.As confirmed above, the novel compound pechuanin JY of the present invention represented by
제제예 1. 시럽제의 제조방법Formulation Example 1 Manufacturing Method of Syrup
본 발명의 화학식 1의 화합물 및 약학적으로 허용되는 그의 염을 유효성분 2%(중량/부피)로 함유하는 시럽은 다음과 같은 방법으로 제조한다.A syrup containing the compound of
화학식 1 의 화합물의 산부가염, 사카린, 당을 온수 80 g에 용해시켰다. 이 용액을 냉각시킨 후, 여기에 글리세린, 사카린, 향미료, 에탄올, 소르브산 및 증류수로 이루어진 용액을 제조하여 혼합하였다. 이 혼합물에 물을 첨가하여 100 ㎖가 되게 하였다. 상기 부가염은 실시예에 의한 다른 염으로 대치시킬 수 있다.Acid addition salts, saccharin and sugars of the compound of
상기 시럽제의 구성성분은 다음과 같다.The components of the syrup are as follows.
화학식 1 의 화합물의 염산염 ············· 2 gHydrochloride of a compound of
사카린 ·······················0.8 gSaccharin: 0.8 g ·················
당 ························ 25.4 g25.4 g of sugar
글리세린······················ 8.0 gGlycerin ... 8.0 g
향미료 ······················ 0.04 gSpices ··················· 0.04 g
에탄올 ·······················4.0 gEthanol 4.0 g
소르브산 ······················0.4 g0.4 g of sorbic acid
증류수 ·······················정량Distilled water ·····················
제제예 2. 정제의 제조방법Formulation Example 2 Manufacturing Method
유효성분 15 mg이 함유된 정제는 다음과 같은 방법으로 제조한다. A tablet containing 15 mg of active ingredient is prepared by the following method.
화학식 1의 화합물의 염산염 250 g을 락토오스 175.9 g, 감자전분 180 g 및 콜로이드성 규산 32 g과 혼합하였다. 이 혼합물에 10% 젤라틴 용액을 첨가시킨 후, 분쇄해서 14 메쉬체를 통과시켰다. 이것을 건조시키고 여기에 감자전분 160 g, 활석 50 g 및 스테아린산 마그네슘 5 g을 첨가해서 얻은 혼합물을 정제로 만들었다.250 g of hydrochloride of the compound of
상기 정제의 구성성분은 다음과 같다.The components of the tablet are as follows.
화학식 1 의 화합물의 염산염·········· 250 gHydrochloride of the compound of
락토오스 ···················175.9 gLactose ························ 175.9 g
감자전분 ····················180 gPotato starch ··········· 180 g
콜로이드성 규산 ················ 32 gColloidal silicic acid 32 g
10% 젤라틴 용액10% gelatin solution
감자전분 ····················160 gPotato starch · 160 g
활석 ······················ 50 gTalc · 50 g
스테아르산 마그네슘 ··············· 5 gMagnesium stearate 5 g
제제예 3. 주사액제의 제조방법Formulation Example 3 Preparation of Injection Solution
유효성분 10 mg을 함유하는 주사액제는 다음과 같은 방법으로 제조하였다.Injection solution containing 10 mg of the active ingredient was prepared by the following method.
화학식 1 의 화합물·염산염 1 g, 염화나트륨 0.6 g 및 아스코르브산 0.1 g을 증류수에 용해시켜서 100 ㎖을 만들었다. 이 용액을 병에 넣고 20℃에서 30 분 간 가열하여 멸균시켰다.1 g of a compound of the general formula (1), hydrochloride, 0.6 g of sodium chloride, and 0.1 g of ascorbic acid were dissolved in distilled water to make 100 ml. The solution was bottled and sterilized by heating at 20 ° C. for 30 minutes.
상기 주사액제의 구성성분은 다음과 같다.The components of the injection solution are as follows.
화학식 1 의 화합물의 염산염···········1 gHydrochloride of the compound of
염화나트륨···················0.6 gSodium Chloride ・ ・ ・ ・ 0.6 g
아스코르브산··················0.1 g0.1 g of ascorbic acid
증류수·····················정량Distilled water ·············
상기에서 확인된 바와 같이, 화학식 1로 표시되는 본 발명의 신규화합물 페츄나닌 JY는 우수한 항산화효과를 나타내므로 항산화효과에 의해 피부 노화를 억제할 수 있는 화장료 조성물로 제조될 수 있다.As confirmed above, the novel compound Pethunanin JY of the present invention represented by
제형예 1: 유연화장수(스킨로션)Formulation Example 1: Softener (Skin Lotion)
하기의 성분과 함량으로 통상의 방법에 따라 유연화장수를 제조하였다.According to the conventional method with the following ingredients and contents were prepared in the flexible cosmetic water.
화학식 1 의 화합물의 염산염 ··········· 0.5 gHydrochloride of the compound of
화학식 1의 화합물을 포함하는 유색감자 추출물 ·· 5.0 gColored potato extract comprising a compound of
1,3-부틸렌글리콜 ················ 6.0 g6.0 g of 1,3-butylene glycol
글리세린 ····················· 4.0 gGlycerin ・ ・ ・ ・ ・ ・ 4.0 g
올레일알콜 ········· ···········0.1 gOleo-alcohol ················· 0.1 g
폴리솔베이트 ·················· 20.5 gPolysorbate ················ 20.5 g
에탄올 ····················· 15.0 gEthanol 15.0 g
벤조페논-9 ·················· 0.05 gBenzophenone-9 0.05 g
향, 방부제 미량Incense, preservative trace
정제수 To 100Purified Water To 100
제형예 2. 영양화장수(밀크로션)Formulation Example 2. Nutrients (Milk Lotion)
하기의 성분과 함량으로 통상의 방법에 따라 영양화장수를 제조하였다.Nutrients were prepared according to a conventional method with the following ingredients and contents.
화학식 1 의 화합물의 염산염 ········· 1.0 gHydrochloride of a compound of
화학식 1의 화합물을 포함하는 유색감자 추출물 · 10.0 gColored potato extract comprising a compound of formula 110.0 g
프로필렌글리콜 ················ 6.0 gPropylene Glycol 6.0 g
글리세린 ··················· 4.0 gGlycerin ・ ・ ・ ・ ・ ・ ・ 4.0 g
트리에탄올아민 ················ 1.2 gTriethanolamine 1.2 g
토코페닐아세테이트 ·············· 3.0 gTocophenylacetate ・ ・ ・ 3.0 g
유동파라핀 ·················· 5.0 gLiquid paraffin 5.0 g 5.0 g
스쿠알란 ··················· 3.0 gSqualane 3.0 g
마카다이아너트오일 ·············· 2.0 gMacadamia nut oil 2.0 g
폴리솔베이트 60 ··············· 1.5 gPolysorbate 60 1.5 g
솔비탄세스퀴올레이트 ············· 1.0 gSorbitan sesquioleate 1.0 g
카르복시비닐 폴리머 ············· 1.0 gCarboxyvinyl Polymers 1.0 g
비에이치티이 ················ 0.01 gBH ... 0.01 g
EDTA-2Na ·················· 0.01 gEDTA-2Na ..... 0.01 g
향, 방부제 미량Incense, preservative trace
정제수 To 100Purified Water To 100
제형예 3. 영양크림Formulation Example 3. Nutrition Cream
하기의 성분과 함량으로 통상의 방법에 따라 영양크림을 제조하였다.The nutrition cream was prepared according to a conventional method with the following ingredients and contents.
화학식 1 의 화합물의 염산염 ············ 2.5 gHydrochloride of the compound of
화학식 1의 화합물을 포함하는 유색감자 추출물 ···· 2.0 gColored potato extract comprising the compound of
세토스테아릴알콜 ·················· 2.0 gCetostearyl alcohol ... 2.0 g
글리세릴스테아레이트 ················ 1.5 gGlyceryl stearate 1.5 g
트리옥타노인 ···················· 5.0 gTrioctanoine ············ 5.0 g
폴리솔베이트 60 ·················· 1.2 gPolysorbate 60 1.2 g
솔비탄스테아레이트 ················· 0.5 gSorbitan stearate 0.5 g
스쿠알란 ······················ 5.0 gSqualane 5.0 g 5.0 g
유동파라핀 ····················· 3.0 gLiquid paraffin 3.0 g 3.0 g
싸이클로메치콘 ··················· 3.0 gCyclomethicone ····· 3.0 g
비에이치티이 ···················· 0.05 gBH T · 0.05 g ···············
델타-토코페롤 ···················· 0.2 gDelta-tocopherol ... 0.2 g
농글리세린 ····················· 4.0 gConcentrated glycerin ············ 4.0 g
1,3-부틸렌글리콜 ··················· 2.0 g1,3-butylene glycol 2.0 g
잔탄검 ························ 0.1 gXanthan Gum · 0.1 g
EDTA-2Na ······················· 0.05 gEDTA-2Na ... ·················· 0.05 g
향, 방부제 미량Incense, preservative trace
정제수 To 100Purified Water To 100
제형예 4. 마사지크림Formulation Example 4 Massage Cream
하기의 성분과 함량으로 통상의 방법에 따라 마사지크림을 제조하였다.Massage cream was prepared according to a conventional method with the following ingredients and contents.
화학식 1 의 화합물의 염산염 ············ 1.0 gHydrochloride of a compound of
화학식 1의 화합물을 포함하는 유색감자 추출물 ···· 0.5 gColored potato extract comprising the compound of
프로필렌글리콜 ··················· 6.0 gPropylene Glycol 6.0 g
글리세린 ······················ 4.0 gGlycerin ... 4.0 g
트리에탄올아민 ··················· 0.5 gTriethanolamine 0.5 g
밀납 ························ 2.0 gBeeswax 2.0 g
토코페릴아세테이트 ················· 0.1 gTocopheryl Acetate ・ ・ ・ ・ 0.1g
폴리솔베이트 60 ·················· 3.0 gPolysorbate 60 ... 3.0 g
솔비탄세스퀴올레이트 ················ 2.5 gSorbitan sesquioleate 2.5 g
세테아릴알코올 ··················· 2.0 gCetearyl Alcohol ... 2.0 g
유동파라핀 ····················· 30.0 gLiquid paraffin 30.0 g ··········
카르복시비닐 폴리머 ················· 0.5 gCarboxyvinyl Polymers 0.5 g
향, 방부제 미량Incense, preservative trace
정제수 To 100Purified Water To 100
제형예 5. 팩Formulation Example 5 Pack
하기의 성분과 함량으로 통상의 방법에 따라 팩을 제조하였다.The pack was prepared according to a conventional method with the following ingredients and contents.
화학식 1 의 화합물의 염산염 ············· 1.0 gHydrochloride of the compound of
화학식 1의 화합물을 포함하는 유색감자 추출물 ····· 1.0 gColored potato extract comprising the compound of
프로필렌글리콜 ···················· 2.0 gPropylene Glycol 2.0 g
글리세린 ······················· 4.0 gGlycerin ················ 4.0 g
카르복시비닐 폴리머 ·················· 0.3 gCarboxy vinyl polymer0.3 g 0.3 g
에탄올 ························ 7.0 gEthanol 7.0 g
피이지-40 히드로게네이티드 캐스터 오일 ········ 0.8 gFiji-40 Hydrogenated Castor Oil 0.8 g
트리에탄올아민 ···················· 0.3 gTriethanolamine 0.3 g 0.3 g
비에이치티이 ····················· 0.01 gBH ... 0.01 g
EDTA-2Na ······················· 0.01 gEDTA-2Na ..... 0.01 g
향, 방부제 미량Incense, preservative trace
정제수 To 100Purified Water To 100
상기에서 확인된 바와 같이, 화학식 1로 표시되는 본 발명의 신규화합물 페츄나닌 JY는 우수한 항산화 및 항암효과를 나타내므로 암이나 다양한 질병에 대한 예방용 건강기능식품으로 제조될 수 있다.As confirmed above, the novel compound pethunanin JY of the present invention represented by
제조예 1. 캔디Preparation Example 1 Candy
하기의 제조비로 캔디를 제조하였다.Candy was prepared at the following preparation costs.
화학식 1 의 화합물을 포함하는 유색감자 추출물 ····· 10.5 gColored potato extract comprising the compound of
설탕 ·······················50.0 g50.0 g of sugar
물엿 ······················ 24.0 gStarch syrup 24.0 g
향료 ······················ 0.5 g0.5 g of spices ······
물························ 15 g 15 g of water
제조예 2. 정과Preparation Example 2
하기의 제조비로 정과를 제조하였다.Fruits were prepared at the following preparation rates.
화학식 1 의 화합물을 포함하는 유색감자 추출물·· 10.5 gColored potato extract comprising a compound of
설탕 ·················· 66.4 g66.4 g of sugar
글루코오스 ················ 19.0 gGlucose ... 19.0 g
자당지방산에스테르 ············ 0.2 gSucrose Fatty Acid Ester 0.2 g
향료 ················ 0.2 g0.2 g of fragrance
물 ················ 3.7 g3.7 g of water
도 1은 유색감자 자영(S. tuberosum L. cv Jayoung. )으로부터 분리한 본 발명의 신규화합물의 HPLC 크로마토그램(detected at 530 nm)을 나타낸 것이다.Figure 1 shows the HPLC chromatogram (detected at 530 nm) of the novel compound of the present invention isolated from S. tuberosum L. cv Jayoung.
도 2와 도 3은 본 발명의 신규화합물 페츄나닌 JY의 항산화활성을 나타낸 그래프이다.2 and 3 are graphs showing the antioxidant activity of the novel compound pethunanin JY of the present invention.
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090083403A KR101162511B1 (en) | 2009-09-04 | 2009-09-04 | New Anthocyanin Isolated from Purple-Fleshed Potatoes and Preparing Method For the Same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090083403A KR101162511B1 (en) | 2009-09-04 | 2009-09-04 | New Anthocyanin Isolated from Purple-Fleshed Potatoes and Preparing Method For the Same |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20110025370A true KR20110025370A (en) | 2011-03-10 |
KR101162511B1 KR101162511B1 (en) | 2012-07-05 |
Family
ID=43932934
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020090083403A KR101162511B1 (en) | 2009-09-04 | 2009-09-04 | New Anthocyanin Isolated from Purple-Fleshed Potatoes and Preparing Method For the Same |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101162511B1 (en) |
-
2009
- 2009-09-04 KR KR1020090083403A patent/KR101162511B1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
KR101162511B1 (en) | 2012-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101133043B (en) | Process for producing proanthocyanidin oligomer | |
KR101174497B1 (en) | Extracts from young barley leaves including polyphenol compounds and their manufacturing method | |
KR101182630B1 (en) | Anthocyan derivative with improved structural stability and synthesis method for the same | |
KR101175195B1 (en) | Composition for prevention and treatment of anti-inflammatory effects comprising purple pigments isolated from purple-potato | |
KR101749497B1 (en) | Composition for skin whitening, or preventing and improving skin hyper-pigmented diseases comprising compound separated from Sedum takesimense as active ingredient | |
KR101611853B1 (en) | Aster glehni fractions or compounds isolated therefrom having anti-inflammatory activity | |
KR101121590B1 (en) | Antioxidant composition comprising isorhamnetin-3-glucoside-7-rhamnoside isolated from hippophae rhamnoides leaves | |
KR101630782B1 (en) | Glucosinolate Compound from Broccoli and Composition Having Antioxidant and Antimicrobial Activity Comprising the Same | |
KR101162511B1 (en) | New Anthocyanin Isolated from Purple-Fleshed Potatoes and Preparing Method For the Same | |
KR20110074189A (en) | Anthocyan derivative with improved structural stability and synthesis method for the same | |
KR100514916B1 (en) | Composition comprising the extract and flavonoid compounds isolated from Nelumbo nucifera stamen having antioxidation activity | |
KR101889331B1 (en) | A composition having anti-oxidation, anti-inflammation or anti-bacterial activity comprising Acanthopanax koreanum Nakai stem extracts, fractions thereof or compounds isolated therefrom as an active ingredient | |
KR20110132766A (en) | Composition for prevention and treatment of gout, hypertension and cancer comprising acanthopanax senticosus fruits extracts | |
KR101963841B1 (en) | Antioxidant composition comprising polyamine compounds isolated from Quercus Mongolica pollen extracts | |
KR101178500B1 (en) | Compounds from Gloiopeltis furcata and Composition for the prevention and treatment of Alzheimer's disease | |
JP2008174458A (en) | 2-ACYLPHLOROGLUCINOL-4,6-DI-C-beta-D-GLUCOPYRANOSIDE HAVING ANTIOXIDANT ACTION | |
KR101797843B1 (en) | A composition having anti-inflammation or anti-bacterial activity comprising Acanthopanax koreanum Nakai stem extracts, fractions thereof or compounds isolated therefrom as an active ingredient | |
KR20140044223A (en) | A pharmaceutical composition comprising extract of uv-induced rice for preventing or treating a colon cancer | |
KR20140106255A (en) | Novel compound having antioxidant activity isolated from mycelial culture of Coprinus echinosporus and antioxidant composition comprising the same | |
KR102014685B1 (en) | Compound from Caragana sinica and composition for skin whitening comprising the same | |
KR101458465B1 (en) | Novel tomentin derivates from Paulownia tomentosa and using thereof | |
KR101309114B1 (en) | Isoindolinone affiliated antioxidation compound isolated from Daldinia concentrica and isolation method thereof | |
KR100597233B1 (en) | New sesquiterpene compound and a process for the preparation | |
KR101866022B1 (en) | Cosmetic composition for skin whitening containing Campylotropis hirtella extract with inhibitory activity of tyrosinase and melanin formation | |
KR100398317B1 (en) | Cytoprotective Agent Comprising Green Tea Catechins as an Active Ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20160324 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20181030 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20190624 Year of fee payment: 8 |